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Although hypertension (HTN) is a major risk factor for stroke, myocardial infarction, and 
kidney failure and contributes to over 350,000 deaths annually in the United States, we know 
surprisingly little about its development or the mechanisms by which it promotes cardiovascular 
disease (CVD). Blood pressure (BP) is complex and tightly regulated by the integrated control of 
multiple organs including the brain, heart, kidneys, GI tract, endocrine and vascular systems. A 
key feature of HTN is increased peripheral vascular resistance which is controlled primarily by 
vascular smooth muscle cell (SMC) contractility.  We identified a SMC-specific RhoA-GAP 
(termed GRAF3) that is critical for limiting RhoA dependent SMC contractility and for 
controlling BP homeostasis.  The work presented below aimed to assess the therapeutic potential 
of GRAF3 and to identify its mechanisms of biochemical regulation.  
Excitingly, to this end, we found that SMC overexpression of GRAF3 resulted in a 
significant 10 mmHg reduction in basal systolic BP—a reduction that was maintained throughout 
L-NAME induced HTN. Interestingly, based on molecular modeling and in vitro experiments, 
we found that the GAP activity of GRAF3 is inhibited by an auto-regulatory interaction between 
the GRAF3 BAR-PH domains and the GRAF3 GAP domain.  Furthermore, we used our models 
to predict important sites of post-translational modifications.  We were able to show that Y367 is 
the major site of GRAF3 activation and phospho-mimetic variants show enhanced GAP activity 
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and decreased RhoA activity, indicating the importance of this site for GRAF3 functionality.  
Moreover, we showed that Src and FAK kinases phosphorylate GRAF3 at Y376 as part of a 
mechanotransduction feedback loop. 
During this project, we discovered the potential importance of another seemingly SM-
specific RhoGAP, GRAF2.  We set out to discover whether the role of GRAF2 overlaps that of 
GRAF3 and found that not only does GRAF2 depletion lead to an increase in basal BP, but it 
also upregulates SMC gene expression and may play a role in arterial stiffening, another feature 
common to CVD. Collectively, the work presented in this dissertation may aid in the 
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CHAPTER 1: INTRODUCTION1 
 
Although hypertension (HTN) is a major risk factor for stroke, myocardial infarction, and 
kidney failure and contributes to over 350,000 deaths annually in the United States1, we know 
surprisingly little about its development or the mechanisms by which it promotes cardiovascular 
disease (CVD). A number of antihypertensive drugs are available, but regimens are usually 
chosen empirically and multiple drugs that target different organ systems are frequently required 
for effective treatment. One reason for these difficulties is that blood pressure (BP) is a complex 
trait that is regulated by many organ systems and a large number of humoral factors. Thus, a 
better understanding of the molecular and genetic mechanisms that control BP under normal and 
pathologic conditions should lead to novel drug targets and/or to personalized therapies that are 
more effective and less toxic. Recent advances suggest that RhoA signaling plays a role in the 
development of human HTN.  The focus of this introduction will be 1) to provide a very brief 
overview of HTN, 2) to highlight the mechanisms underlying RhoA-dependent regulation of BP, 
3) to summarize the current data on the strategies and efficacy of targeting this pathway in 
hypertensive patients, and 4) to state the objectives of this dissertation.  
                                               
1 This chapter contains text and figures previously published in the following review articles: 
 Bai X, Dee R, Mangum K, Mack C and Taylor J. RhoA signaling and blood pressure: The consequence of failing  
          to Tone it Down". World J Hypertens. 2016;6:18-35.  
Dee RA, Mangum KD, Bai X, Mack CP and Taylor JM. Druggable targets in the Rho pathway and their promise   
          for therapeutic control of blood pressure. Pharmacol Ther. 2019;193:121-134. 
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1.1  A brief overview of hypertension 
Hypertension is a major cardiovascular risk factor that significantly increases the 
incidence of stroke, myocardial infarction, heart failure, retinopathy, and kidney disease2.  
Although HTN is one of the most modifiable cardiovascular risk factors, the number of 
individuals with HTN is increasing world-wide. Further amplifying the importance of HTN, the 
American Heart Association has recently revised its definition of Stage 1 HTN to include 
individuals with systolic BP between 130 and 139 mmHg or diastolic BP between 80 and 89 
mmHg.  This change was prompted by studies demonstrating beneficial effects of lowering BP 
below the 120/80 mmHg threshold3-5 and effectively increased the number of Americans 
categorized as hypertensive from 32% to 46%5.  It is also becoming clear that many people 
suffer from masked HTN (normal readings in the clinic, but hypertensive outside the clinic) and 
non-dipping HTN (steady BP through the day but no decrease in BP at night)6-8, suggesting that 
more intensive BP monitoring would identify additional at-risk individuals9.   
A number of relatively inexpensive first-line therapies are available to treat HTN 
including diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II (AII) 
receptor blockers, and calcium channel blockers.  However, these drugs are usually prescribed 
empirically and are often ineffective. Indeed, over 50% of adults who are being treated for HTN 
still do not have their BP under control10.  Although treatment can be improved by multidrug 
regimens that target different BP control mechanisms, 13% of treated patients have drug-
resistant HTN and remain hypertensive even after taking three 3 or more medications, or require 
4 medications for adequate BP control11, 12.  Taking multiple BP medications also increases the 
risk of unwanted side effects and drug-drug interactions.  While incomplete health history and 
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poor patient compliance contribute to the difficulties in treating HTN, our lack of understanding 
of the etiology of HTN is also a major factor.  
Many of the difficulties of treating HTN stem from the fact that BP is an extremely 
complex trait regulated by many organ systems. Although the major determinants of BP are 
cardiac output and systemic vascular resistance, BP homeostasis requires proper regulation of 
heart and vasculature function by the autonomic nervous system, kidneys, and endocrine organs. 
The fact that these systems are tightly integrated by many feedback loops further complicates our 
understanding of the development of HTN and its treatment. Nearly all heritable genetic 
mutations that cause HTN affect kidney function and/or salt balance, but these variants only 
explain about 10% of HTN cases. More recent genome wide association studies (GWAS) have 
identified many genetic loci that correlate with relatively small differences in BP between 
populations. However, because most of these variations are within or near genes with no known 
connection to BP regulation, our understanding of how they affect the development of HTN is 
limited. A number of the genes identified by GWAS are highly expressed in endothelial and 
smooth muscle cells (SMCs), highlighting the importance of the vasculature as a major regulator 
of BP and as a target for potential therapies13-16.  
 
1.2  Impact of the RhoA pathway on blood pressure homeostasis 
The 22 members of the Rho family of small GTPases can be divided into three major 
subfamilies: Rac, RhoA, and Cdc42. The RhoA family of GTPases (RhoA, RhoB, and RhoC) are 
widely expressed and share 85%  amino acid homology including a C-terminal cysteine residue 
that is the target of geranylgeranylation, a post-translational modification that anchors RhoA 
family proteins to the plasma membrane.  As discussed below, RhoA is by far the most studied 
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member of this subfamily and has been shown to regulate a variety of cellular processes 
including (but not limited to) actin and microtubule dynamics, cell force, cell shape and polarity, 
endocytosis, exocytosis, cell adhesion and migration, proliferation, and differentiation17, 18.  
Like all GTPases, RhoA is regulated by guanosine triphosphate (GTP) binding and cycles 
between the active GTP-bound form and the inactive guanosine diphosphate (GDP)-bound form 
and this cycle is under the direct control of three groups of regulatory protein; guanine 
dissociation inhibitors (GDIs) sequester RhoA into an inactive cytoplasmic fraction, guanine 
nucleotide exchange factors (GEFs) activate RhoA by facilitating exchange of GDP for GTP, 
and GTPase activating proteins (GAPs) promote RhoA’s intrinsic GTPase activity to hydrolyze 
GTP to GDP and efficiently turn off (or limit) RhoA-dependent signaling.  When GTP-bound, 
RhoA interacts with a variety of effector molecules that mediate its varied functions including 
the Rho-associated coiled-coil domain containing protein kinases (ROCK I and II), the 
diaphanous-related formins (mDia1 and mDia2), protein kinase N, citron kinase, rhophilin, and 
the rhotekins I and II, among other enzymes17.  
Recent advancements suggest that RhoA signaling in the vasculature is a particularly 
attractive target for therapeutic intervention in the treatment of HTN.  With respect to regulation 
of BP, Rho kinases are arguably the most important effectors as evidenced by the findings that 
increased ROCK activity has been observed in spontaneously hypertensive rats and some 
hypertensive patient populations19, 20 and that ROCK inhibitors like Y-27632, Fasudil, and 
SAR407899 have been shown to reduce BP in hypertensive animal models and patients21. 
Extensive studies have shown RhoA signaling enhances Ca2+-dependent, myosin-based force 
production in vascular SMCs and recent studies from our lab and others have implicated several 
components of the RhoA signaling pathway in the development of HTN in mouse models19, 20, 22.  
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Moreover, human genetic studies have identified BP-associated variants in several additional 
Rho-related genes further implicating this pathway in human HTN23.  
Although Rho signaling components are relatively strongly expressed in vascular SMCs, 
nearly all, with the exception of the RhoGAP GRAF3, are expressed in many other tissues. Thus, 
when evaluating Rho signaling molecules as targets of anti-HTN therapy, it is important to 
consider the potential impact of modulating Rho-signaling in other organ systems. Interestingly, 
with respect to BP regulation, studies using pre-clinical models indicate that attenuating RhoA 
signaling in the vasculature, kidney, myocardium, and CNS could all lead to the desired outcome 
of lowering BP.   
 
1.2.1  RhoA and arteriole tone  
 Vascular resistance is a major determinant of BP and is controlled, in large part, by 
smooth muscle cell contraction within small peripheral arterioles24-28.  Mechanistically, 
excitation-contraction coupling in SMCs is mediated by the Ca2+-dependent activation of myosin 
light chain kinase (MLCK), and SMC tension is directly proportional to myosin light chain 
(MLC) phosphorylation at S19 as this enables myosin’s molecular interaction with actin29, 30 
(Figure 1.1).  Interestingly, besides promoting an inositol triphosphate-mediated increase in 
intracellular Ca2+, many circulating GPCR-coupled contractile agonists including AII, 
norepinephrine, endothelin-1 (ET1), and sphingosine-1-phosphate (S1P) also stimulate RhoA 
activity in SMCs and in intact arteries which further enhances Ca2+-dependent SMC 
contractility19, 20, 22.  Active RhoA leads to ROCK-dependent inhibition of myosin phosphatase 
and results in elevated MLCK activity and enhanced sensitization to Ca2+ 19, 31-33.  Importantly, 
several studies in animal models and patients (described in further detail below) indicate that 
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RhoA-dependent pathways are involved in the increased vascular resistance associated with 
hypertension19-22, 34. 
Studies in genetically engineered mice revealed that germline deletion of the Rho-
specific GEF, LARG, significantly attenuated salt-induced HTN35, while SMC-specific knockout 
of the related GEF, p115RhoGEF, inhibited the development of HTN in response to AII20. In 
addition, we recently showed that depletion of the SMC-selective, Rho-specific GAP, GRAF3 
(ArhGAP42) in mice leads to basal HTN, increased pressor responses to AII, ET1, and 
phenylephrine (PE), and elevated deoxycorticosterone-acetate (DOCA)-salt induced HTN36-38.   
RhoA regulates several effector molecules that impact SMC contractility (Figure 1.1). 
Direct phosphorylation of MLC by ROCKs I and II promotes actin-myosin crossbridge cycling 
as does ROCK dependent inhibition of MLC phosphatase (MLCP). RhoA activity is also critical 
for de novo formation of actin filaments and formation of focal adhesions that are required for 
myosin-dependent force development and transmission, respectively.  The Rho effectors mDia 1 
and 2 are the most potent regulators of actin filament formation as these proteins function to 
directly catalyze actin polymerization in cooperation with the actin binding protein, profilin. 
ROCKs also inhibit actin de-polymerization by phosphorylating and activating LIM-kinase 1 and 
2 (on Thr 508 or 505 respectively), which in turn, phosphorylate and inhibit the actin filament 
severing protein, cofilin39-42.  Finally, ROCK-dependent phosphorylation of ezrin-radixin-moesin 
(ERM) proteins promotes their tethering to integral plasma membrane proteins effectively 
stabilizing actin filaments and increasing force transmission43.   
In addition to promoting acute changes in SMC contractility, recent studies indicate that 
RhoA signaling also controls the transcription of numerous contractile genes by modulating 
serum response factor (SRF) activity.  SRF binds to CArG (CC(A/T)6GG) cis elements located 
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within the promoters of nearly all SMC contractile genes (including SM myosin heavy chain, 
SM22, calponin, and SM α-actin)44.  SRF activity is modulated by transcription cofactors of the 
myocardin family45-49 and two such co-factors, myocardin transcription factor A and B (MRTF-
A and MRTF-B) mediate strong trans-activation of SMC contractile genes50, 51.  We have 
previously demonstrated that RhoA promotes SMC contractile gene expression through actin 
polymerization-dependent regulation of MRTF-A and MRTF-B nuclear localization44, 51-54. 
Cytoplasmic monomeric G-actin is abundant when RhoA activity is low (for example in SMC 
under low tension55), and under these conditions, G-actin binds to MRTF and masks an N-
terminal nuclear localization sequence, resulting in cytoplasmic sequestration of these SRF co-
factors.  Upon RhoA activation, G-actin is recruited into growing F-actin filaments and MRTF-
G-actin association decreases.  As a consequence, MRTF nuclear localization sequence is un-
masked, and MRTF accumulates in the nucleus and promotes SRF-dependent gene expression56.  
Moreover, elevated RhoA in endothelial cells impairs endothelial cell-mediated vasorelaxation 
as it decreases availability of the potent vasodilator, nitric oxide by reducing both eNOS 
expression and activity57-61.  Thus, signaling through RhoA in small arteriolar SMC enhances 
Ca2+ sensitivity, promotes actin remodeling and induces expression of contractile proteins and 
these responses are necessary for maintaining sustained SMC contractility and elevated vessel 
tone.    
 
1.2.2  RhoA and kidney function   
The kidneys play a major role in regulating BP by controlling sodium excretion and 
blood volume. In addition, since the kidneys are highly perfused organs receiving up to 25% of 
total cardiac output, increased contractility of renal arterioles can significantly increase total 
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peripheral vascular resistance. In most vascular beds, arteriolar tone is controlled by autonomic 
innervation and circulating hormones. However, in pre-glomerular afferent arterioles, increased 
kidney perfusion (manifesting as increased renal BP) stimulates SMC contraction through the 
tubuloglomerular feedback and myogenic responses (see 62 for review).  The former mechanism 
is mediated by increased glomerular filtration and NaCl delivery from the loop of Henle to the 
macula densa (MD), a cluster of epithelial cells located at the junction between the distal 
convoluted tubule and the end of the thick ascending limb and adjacent to the abluminal SMCs 
of the afferent arterioles.  Increased NaCl uptake by MD cells results in secretion of ATP and 
adenosine which stimulate afferent arteriole SMC contraction via P2Y4/P2Y6 and A2 GPCRs, 
respectively63-68.  The myogenic response is mediated by the activation of stretch-sensitive cation 
channels. Together these mechanisms stabilize renal blood flow to protect the sensitive 
glomerular capillaries from flow-induced trauma.  Importantly, afferent arterioles express RhoA, 
ROCK I and II68, and several studies have convincingly demonstrated that the Rho/Rho kinase 
pathway influences both of these feedback mechanisms in response to increased kidney 
perfusion63-67. The requirement of RhoA is likely due, at least in part, to its necessity for 
P2Y4/P2Y6 and A2 receptor-dependent contractility.  Indeed, ATP (via P2Y4/Y6) and 
adenosine (via A2) stimulate RhoA activity in SMC and their pressor responses were prevented 
by pretreatment with the Rho-kinase inhibitor, Y-2763268. 
Interestingly, recent evidence indicates that RhoA may play an additional role in other 
cell types within the kidney to impact volume homeostasis.  In particular, RhoA activity in 
tubular epithelial cells can regulate sodium reabsorption and excretion primarily by altering the 
density and location of epithelial sodium channels (ENaCs) and the sodium-hydrogen exchanger 
(NHE3)69.  In vitro studies in cultured epithelial cells indicated that the Na+ current through 
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ENaCs was significantly increased by expression of wildtype or constitutively active RhoA 
(G14V) and suppressed by expression of dominant negative RhoA (T19N).  The changes in 
current correlated with alterations in the density of ENaCs at the PM70 and mechanistic studies 
determined that RhoA signaling was essential for intracellular vesicle mediated transport of 
ENaCs to the apical cell surface71, 72.  RhoA signaling also regulates the activity and subcellular 
localization of NHE3, a key regulator of sodium absorption in the proximal convoluted tubule. 
NHE3 associates with ezrin and cortical actin filaments at the plasma membrane and treatment 
with either the RhoA inhibitor, diarrheal toxin toxin B, or Y-27632 disrupted these interactions 
and promoted the internalization of NHE3 to sub-membrane compartments73, 74.  Moreover, 
Nishiki et al. showed that spontaneously hypertensive rats exhibited elevated NHE3 activity and 
an exaggerated level of Na+ reabsorption when compared to normotensive controls and that Na+ 
reabsorption was normalized by treatment of the hypertensive animals with Y2763275.   
 
1.2.3  RhoA in the central and peripheral nervous system  
The central nervous system (CNS) constantly assesses pressure levels in the vasculature 
and makes necessary signaling adjustments to prevent BP variability. The main mechanism by 
which the CNS monitors BP is through a rapid negative feedback loop termed the baroreceptor 
reflex.  Baroreceptors are sensory neurons located primarily in the aortic arch and carotid sinuses 
that continuously respond to pressure-induced stretching of the vessels in which they reside.  
Impulses from baroreceptors are relayed via glossopharyngeal and vagus nerves to the nucleus 
tractus solitarii (NTS) in the brainstem76, which in turn relays the signal to the rostral 
ventrolateral medulla77 and increases or decreases parasympathetic and sympathetic stimulation 
to the heart and vessels accordingly.  Interestingly, the CNS component of this feedback loop has 
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been shown to be dependent on RhoA/Rho-kinase signaling.  Rho-kinase inhibitors 
microinjected directly into the NTS or infection of this structure with an adenovirus expressing a 
dominant-inhibitory form of Rho-kinase reduces sympathetic nerve activity, heart rate, and BP in 
normotensive rats and these effects are even more pronounced in spontaneously hypertensive 
rats78, 79.  Moreover, infusing the ROCK inhibitor, Y27632, into the neural cistern attenuated the 
BP increase that resulted from AII infusion into the same area of the brainstem80.  
Recent studies indicate that the RhoA pathway may also regulate neurotransmitter release 
from perivascular nerves.  Some studies in cells and invertebrate model systems indicate that 
inhibition of Rho/Rho kinase signaling in motor neurons antagonized the secretion of 
parasympathetic relaxation factors (including acetylcholine) and promoted the secretion of  
sympathetic contractile agonists (including dopamine)81, 82.  Yamaguchi et al. found that Gα12/13-
mediated activation of RhoA/ROCK inhibited Ca2+ dependent  exocytosis81. In support of these 
studies, an activating mutation in ArhGEF10, a RhoGEF highly expressed in the peripheral 
nervous system, was identified in patients who exhibited slowed nerve conduction velocities83, 84.  
Thus, it is possible that RhoA's ability to block neurotransmitter release in peripheral nerves 
could affect vascular tone and BP but such outcomes may limit the therapeutic efficacy of 
RhoA/ROCK inhibitors as future anti-hypertensive therapies.   
 
1.2.4  RhoA in the myocardium  
Several studies have shown that RhoA signaling has direct effects on cardiac function 
that increase cardiac output and BP.  Transgenic mice that overexpressed either GDIa or 
dominant negative RhoA exhibited conduction defects and cardiomyocytes isolated from these 
mice exhibited decreased L-type Ca2+ channel currents that likely contributed to the decreased 
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contractility observed in vivo85, 86.   Vlasblom et al. showed that treatment of neonatal ventricular 
cardiomyocytes with Y27632 reduced the expression and activity of the sarcoplasmic reticulum 
Ca2+ ATPase, SERCA2a, thereby limiting the amount available for Ca2+ -induced Ca2+  release 
in the next cardiac cycle87.  In addition, RhoA-dependent pathways have been shown to be 
critical for phosphorylation and sensitization of cardiac troponin T complex to intracellular Ca2+ 
levels88. Moreover, while not initially thought to be a major mechanism for modulating cardiac 
contractility, it is becoming clear that cardiac MLC phosphorylation can enhance muscle 
contractility by increasing Ca2+ sensitivity 89and that MLC phosphatase is a target for Rho 
kinase-dependent inhibition in the myocardium (like in SMC).  Indeed, Lauriol et al. showed that 
cardiac-restricted deletion of RhoA led to decreased contractility and this effect was correlated 
with decreased MLC activity90.  Other similarities between RhoA signaling in cardiomyocytes 
and SMC include the ability of RhoA-mediated signals to promote differentiation/maturation by 
promoting the expression of contractile genes91.  
 
1.3. Targeting the RhoA pathway for therapeutic blood pressure control 
In agreement with the pre-clinical animal studies highlighted above, several lines of 
evidence strongly implicate RhoA signaling in the development of human HTN.  First, increased 
Rho-kinase activity has been observed in some hypertensive patient populations, reviewed 
below.  Rho kinase inhibitors have been successful in reducing systemic HTN in these cases, 
although current formulations exhibit relatively short-term effects23, 92, 93.  Second, an autosomal 
dominant mutation in the E3 ligase, Cullin-3 (which targets RhoA), has been shown to cause 
high BP in patients with Gordon’s Syndrome (pseudohypoaldosteronism type IIE).  Importantly, 
the identical mutation in pre-clinical mouse models and led to decreased Cullin-3 activity, 
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reduced ubiquitin-mediated RhoA degradation in vascular SMCs, and increased BP94, 95.  Third, 
many GWAS conducted over the past decade have identified common BP-associated genetic 
variations in coding and non-coding regions within or near genes linked to the RhoA signaling 
cascade.  For example, in one study that used HTN as a dichotomous trait, two of the eight BP-
associated loci were located in RhoA-related genes.  One was within RhoBTB1, which functions 
with the aforementioned Cullin-3 complex to maintain low RhoA levels94, 96, while the other was 
within rhotekin-2 (RTKN2), a RhoA effector with unknown function.  Two separate GWAS 
identified a BP-associated locus within PLEKHA7 (Plekstrin Homology domain containing 
family A member 7)97, 98 which interacts with the junctional proteins cingulin and paracingulin to 
regulate several Rho family GTPases, including RhoA in the heart and kidneys99.  Importantly, 
PLEKHA7 was subsequently shown to be required for the development of salt-induced HTN in 
mice100.  Moreover, a few variants in ROCK II have been associated with the regulation of BP.  
Of particular interest was the identification of a common nonsynonymous ROCK II variant 431N 
(versus 431T) that was associated with an increase in BP in twins69, 101-104.  This result was 
supported by Liao et al., who showed that the 431N variant had increased kinase activity and 
was associated with enhanced arterial stiffening, a vascular property strongly associated with 
HTN69, 101-104.  This group identified a second variation in the ROCK II 3'UTR (rs9789060) that 
was also associated with increased stiffening and went on to show it affected ROCK II 
expression by interfering with miR-1183-dependent degradation of ROCK II mRNA levels.  It is 
important to note that a third study failed to find an association between rs9789060 and BP101.  In 
another study on 586 normotensive and 607 hypertensive Caucasians, Rankinen et al. identified 
a minor allele locus within the ROCK II gene that lowered the risk of HTN by 85%. 103.  Finally, 
as discussed in further detail below, three separate GWAS for BP and cardiovascular disease 
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endpoints identified a novel BP associated locus within the Rho-specific GAP, 
GRAF3/ArhGAP4215, 16, 105, 106.  Recent causality studies from our group demonstrated that 
GRAF3 is selectively expressed in SMC and is required for BP homeostasis in mice36-38. 
Collectively, these studies reveal that the RhoA signaling axis may provide tractable 
targets for the treatment of human HTN and related cardiovascular sequela.  Indeed, some 
commonly used anti-hypertensives (i.e. ACE inhibitors, AII blockers, and statins) likely function 
by interfering with RhoA signaling, supporting the clinical utility of inhibiting this pathway22, 107-
109.  Nonetheless, despite the importance of the RhoA pathway in the pathogenesis of HTN and 
several other debilitating diseases including amyotrophic lateral sclerosis, mental retardation, 
hepatocellular, lung, and colorectal carcinomas110-112, surprisingly few treatments are available to 
directly target this pathway.  In fact, of the nearly 300,000 ongoing clinical trials, only a handful 
involve compounds that target RhoA signaling components (clinicaltrials.gov). This could be 
due to the fact that many members of the RhoA pathway (with exception of Rho kinase) have 
traditionally been regarded as “undruggable”.  However, as described below, significant 
advancements in high resolution crystal structures, structure-function analyses and drug 
development technology are beginning to overcome these challenges and provide hope for the 
development of new therapies to target this critical pathway. 
 
1.3.1  Targeting Rho Kinase 
The serine/threonine kinases, ROCK I and ROCK II, are the best studied RhoA effectors 
and have been implicated in a variety of diseases including HTN23.  Since the development of 
kinase inhibitors has proven to be a very successful therapeutic approach, it is not surprising that 
ROCK has been an attractive target in the search for RhoA signaling inhibitors and that ROCK 
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inhibitors are the furthest along in regard to clinical testing.  Because ROCK I and II share 60% 
identity overall, 90% identity within the kinase domain identity, and 100% identity within the 
ATP binding pocket113 they share many substrates and promote many of the same downstream 
cell functions93.  Although ROCK I and ROCK II expression can vary somewhat between 
tissues, both of these kinases are widely expressed113, 114.  Differences in subcellular localization 
have been noted with ROCK I localizing more readily to microtubule-organizing centers115 and 
catenin/E-cadherin containing complexes at the plasma membrane116 and ROCK II to vimentin 
117 and actin fibers118 114, 119.  Isoform-specific inhibitors are being developed that could have 
differential effects depending upon the disease treated or end-point measured23, 120-123 
(clinicaltrials.gov).  
While over 30 common downstream targets of ROCK have been identified (Adducin, 
Diaphanous [mDia], LIM kinase [LIMK], NHE1, MARCKS, NF-L, CRMP2, FAK, c-Jun N-
terminal kinase [JNK], MLC, MLCK, MLCP, ezrin/radixin/moesin [ERM], rhophilin, rhotekin, 
citron kinase, and Tau)23, 93, 119, 124, the most pertinent in regard to SM contraction and BP 
regulation is the myosin binding subunit (MYPT-1) of the MLCP complex.  ROCK-dependent 
phosphorylation of MYPT-1 at T696, T853, and S854 inhibits MLCP activity resulting in 
increased MLC phosphorylation and hence increased contraction114, 125.  ROCK has also been 
shown to directly phosphorylate MLC at S19. 
As reviewed more thoroughly elsewhere23, 93, over 170 ROCK inhibitors are in various 
stages of development (Table 1.1).  Given the involvement of actin-based processes in many 
pathologies (adhesion, migration, cell division, force generation, etc.), ROCK inhibitors are 
being studied as treatments for a wide variety of disease states including central nervous system 
disorders (subarachnoid hemorrhage and vasospasm, cerebral stroke, spinal cord injury), 
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neurodegenerative diseases (Alzheimer’s disease, Parkinson’s, Huntington disease, and 
amyotrophic lateral sclerosis [ALS]), cardiovascular disease (systemic HTN, pulmonary arterial 
HTN [PAH], spastic and stable angina, atherosclerosis, Raynaud syndrome), asthma, glaucoma, 
autoimmune diseases, cancer, erectile dysfunction, and kidney disease.  Although the results of 
these studies and clinical trials provide important information on ROCK and its role in disease 
progression, we will focus our discussion on the major ROCK inhibitors that have been most 
commonly used to treat vascular diseases. 
Fasudil (also known as HA-1077) was the first ROCK inhibitor described and was also 
the first to be tested clinically.  This isoquinoline-based drug is classified as a class I ROCK 
inhibitor because it reversibly competes with ATP binding to the ROCK kinase domain.  Fasudil 
inhibits both isoforms of ROCK with an IC50 of 1µM while hydroxyfasudil, the major active 
metabolite, is slightly more potent with an IC50 of ~0.7µM126.  Like most other ROCK inhibitors 
of this class fasudil also inhibits other members of the broad AGC kinase family including PKA 
and PKC, albeit with less potency (IC50 of 5µM and 37µM, respectively)126, 127.  Fasudil was 
shown to reduce BP by attenuating the Rho-mediated inhibition of MLCP in SMC126, by 
increasing endothelial nitric oxide synthase expression128, and by reducing circulating ACE and 
AII levels129. Fasudil also inhibited pulmonary artery SMC proliferation, a process important for 
vessel stiffening, by a mechanism that likely involved downstream inhibition of c-Jun N-terminal 
kinase (JNK) and ERK-dependent activation of c-jun and c-fos expression130. 
Fasudil hydrochloride hydrate under the trade name Eril® was approved in Japan in 1995 
to treat vasospasm-induced cerebral ischemia that can occur following surgery for subarachnoid 
hemorrhage.  In 2002, Masumoto et al. showed that intracoronary fasudil was effective as an 
acute treatment of vasospastic angina131, and additional clinical trials showed that long-term 
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treatment with oral fasudil reduced stable effort-induced angina and improved exercise tolerance 
with no major adverse effects132, 133.  In a rat model, moderate doses of fasudil decreased PAH 
while higher doses also decreased mean systemic arterial pressure134.  By 2011, intravenous and 
inhaled fasudil were approved to treat PAH135, 136, and a new extended release formulation of 
fasudil, AT-877ER, was shown to reduce PAH in patients after three months of use137. Fasudil 
also decreased forearm vascular resistance more dramatically in hypertensive patients than in 
normotensive controls21.  Fasudil has been shown to have beneficial effects on kidney function in 
diabetic rats138, suggesting that it might be useful for treating diabetic patients who are frequently 
hypertensive and have kidney disease.  Ongoing phase III clinical trials are also assessing 
whether fasudil is an effective treatment for Reynaud’s syndrome and carotid stenosis 
(clinicaltrials.gov).  Fasudil has been approved in China, but not in the United States or Europe. 
Several fasudil derivatives that are more potent and specific inhibitors of ROCK have 
been developed and are being used to treat glaucoma and ocular HTN.  Ripasudil (Glanatec®), 
approved in Japan in 2014, affects the trabecular meshwork in the eye and reduces intraocular 
pressure by facilitating the outflow of aqueous humor through Schlemm’s canal.  The most 
common side effect of ripasudil treatment is conjunctival hyperemia, which subsides over time 
or with discontinued use139.  Netarsudil (Rhopressa ®) has similar effects and indications, and in 
2017, became the first ROCK inhibitor approved by the United States140, 141.  Netarsudil also 
decreased the amount of aqueous humour produced, a feature attributed to additional effects of 
netarsudil as a norepinephrine transport inhibitor140, 141. 
The classic ROCK inhibitor, Y-27632, is a pyridine-based class I inhibitor that has been 
tested in a number of animal and human disease models including HTN.  In a landmark study, 
Uehata et al. demonstrated that Y-27632 decreased BP in spontaneously hypertensive rats 
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(SHR), DOCA-salt treated rats, and rats made hypertensive by clipping of the renal artery142.  
Although mesenteric and cerebral arteries in SHR or DOCA/salt treated rats were more 
responsive to Y-27632 than those in normotensive rats143, 144, Y-27632 likely affected HTN by 
multiple mechanisms.  For example, Y-27632 also reversed the decrease in renal sodium 
excretion observed in the SHR model75, most likely by affecting the activity and location of 
Na+/H+ exchanger, NHE373, 74.  In addition, local infusion of Y-27632 into the nucleus tractus 
solitarius of the brainstem caused a reduction in BP, heart rate, and renal sympathetic nerve 
activity, and the magnitude of these effects was greater in the SHR model78, 79.  Subsequent 
studies by the same group demonstrated that fasudil had similar effects78, 79.  Although Y-27632's 
poor potency and kinase selectivity limit its use clinically, Y-27632 derivatives with better 
pharmacologic properties are being developed and tested. 
SAR407899 is a promising relatively new isoquinoline-based class I ROCK inhibitor that 
is significantly more potent than older generation drugs (IC50 between 122 and 280 nM)145.  In 
vitro studies demonstrated that SAR407899 inhibited myosin phosphatase phosphorylation, 
stress fiber formation, cell proliferation, and monocyte chemotaxis145.  SAR407899 dose-
dependently lowered BP in SHR, stroke-prone SHR, L-NG-Nitroarginine methyl ester (L-
NAME), and DOCA-salt rat models, and its effects in some models was superior to ACE 
inhibitors and calcium channel blockers145.  SAR407899 inhibited pressor responses to PE, AII, 
and vasopressin in rats more strongly than Fasudil or Y-27632, and it inhibited ET1-induced 
vasoconstriction of renal arteries isolated from diabetic rats more strongly than Y-27632146.  In 
spite of its efficient antihypertensive effects and the fact that long term treatment of rats with 
SAR407899 was well-tolerated, development of SAR407899 as an anti-hypertensive has been 
discontinued23.  SAR407899 is still being tested in clinical trials as a treatment for kidney disease 
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and microvascular coronary artery disease and it may prove useful for treatment of erectile 
dysfunction in diabetic and hypertensive patients where the eNO system is impaired147.  
Although ROCK inhibition has been shown to reduce BP and vascular resistance in many 
models, there are concerns about the suitability of ROCK inhibitors as viable long-term 
treatments for systemic HTN.  Although most ROCK inhibitors seem to be fairly well-tolerated, 
the ubiquitous nature of ROCK I and ROCK II expression coupled with the relative lack of 
specificity of most ROCK inhibitors (especially the class I drugs) makes potentially unknown 
side-effects a significant drawback.  While local delivery strategies can sometimes mitigate this 
concern (i.e. to the eye or specific vascular beds)93, 148, systemic hypotension can be a serious 
problem for patients being treated in this manner.  Another potential problem is that the systemic 
BP lowering effects of ROCK inhibitors frequently decrease after 7-10 days of chronic 
treatment93.  Moreover, ROCK inhibitors did not affect systolic BP in some long-term studies of 
salt-sensitive hypertensive Dahl rats69, 75.  The precise causes of this tolerance or inactivity are 
unknown, but likely involve compensation by the many feedback pathways that regulate BP.  
Finally many ROCK inhibitors have short half-lives, which is not ideal for the treatment of a 
chronic disease like HTN149. 
 
1.3.2  Targeting RhoA directly 
Numerous failed attempts to identify small molecule inhibitors of H-Ras have led to the 
concept that small GTPases per se do not make good drug targets due to their globular structure 
and lack of surface moieties required for high affinity binding of small molecules110, 150, 151.  
However, such direct targeting may be the most effective means to reduce signal output given 
that many disease-associated mutations of small GTPases enable GEF-independent activation152, 
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153.  Moreover, in the case of HTN, direct targeting could provide an added benefit over ROCK 
inhibitors, as such an approach would block additional downstream pathways implicated in SMC 
contractility (i.e. mDia1 and mDia2, MRTF, etc.).     
 
1.3.2a  GTP-binding inhibitors 
 Although direct targeting of the GTP binding site of RhoA (or related small GTPases) is 
challenging due to its high affinity for GTP (in the pico to nano-molar range) and the high 
concentration of GTP in cells (~0.5 mM), some studies support the validity of this approach.  
Indeed, using an in silico virtual docking approach followed by surface-plasmon resonance 
validation of synthesized chemicals, Deng et al. identified lead compounds that inhibited Rho-
GTP binding in a dose-dependent fashion with IC50 values ranging from 1.24–2.05 µM154.  After 
further structural modifications to increase water solubility, one compound ((E)-3-(3-
(ethyl(quinolin-2-yl)amino)phenyl)acrylic acid) was shown to both attenuate PE-induced 
contraction in thoracic aorta rings ex vivo and to reduce cerebral vasospasm in a subarachnoid 
hemorrhage model in rats155.  While the in vivo efficacy was similar to that of fasudil, this second 
generation inhibitor still exhibited relatively low potency (IC50 71 µM in the contractile assay).  
Future studies will be necessary to determine whether these or related compounds exhibit 
specificity for RhoA versus other Rho family GTPases and other GTP-binding proteins.   
In support of the possibility of identifying GTP binding inhibitors that can specifically 
target particular Rho-related family members, simultaneous multiplex screening for small 
molecules in the 200,000 Molecular Libraries Screening Center Network library has already 
identified a CDC42 specific inhibitor as well as a broad Ras family inhibitor.  These inhibitors 
prevented GTP binding in a dose-dependent fashion (as noncompetitive allosteric inhibitors) and 
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are active in cell based assays156-158.  The subsequent application of this technology to screen the 
Prestwick Chemical Library of off patent and FDA approved drugs for inhibitors of eight Ras-
related GTPases (but not RhoA, B, or C) led to the identification of R-enantiomers of naproxen 
and ketorolac (approved NSAIDs) as GTP binding inhibitors of Rac1 and Cdc42159.  Although 
not biochemically confirmed, in silico docking analyses predicted that these drugs bind to an 
allosteric site near the GTP binding site that alters Mg2+ ion coordination and results in 
stabilizing the GTPase in its GDP-bound form.  To our knowledge, this approach has not been 
used successfully to identify RhoA specific inhibitors, but these results provide strong proof-of-
concept for this approach. 
 
1.3.2b  Selective non-covalent RhoA modifiers 
The potential for identifying allosteric modifiers to inhibit RhoA has been demonstrated 
by the fact that a number of bacterial toxins are highly potent (though non-selective) inhibitors of 
Rho family members.  For example, Histophilus somni and Vibrio parahemolyticus produce 
toxins that inhibit Rho proteins by promoting the covalent attachment of an AMP molecule to 
tyrosine 34, while toxin B produced by Clostridium difficile induces glucosylation of nearby 
threonine 37.  These residues lie within the regulatory switch-I domain of Rho family members 
and addition of these bulky modifications in this domain inactivate the Rho GTPases by multiple 
mechanisms that include inhibition of GTPase cycling (by blocking GEF and GAP association), 
inhibition of cytosol-membrane cycling (by blocking Rho GDI interactions) and inhibition of 
Rho effector coupling160, 161.  Similarly, Clostridium botulinum exoenzyme C3 transferase toxin 
inhibits RhoA, RhoB, and RhoC in vitro and in vivo by promoting ADP-ribosylation of 
asparagine 41 which blocks GEF binding110, 162.  Such pathogenic agents have been useful as 
  
 21 
pharmacological tools to completely block Rho-dependent signaling pathways in cells and in 
pre-clinical animal models.  However, their potential as therapeutic agents is limited because of 
their difficult delivery, their non-specific actions, and their sometimes covalent and irreversible 
effects110, 163.  Nonetheless, the future exploitation of derivatives or mimetics of such enzymes 
could lead to the development of new inhibitors with tremendous clinical utility.          
Finally, Rho family inactivation can be achieved by blocking plasma membrane 
targeting.  For example, Rho GTPases are isoprenylated on carboxy-terminal Cysteine residues 
(within a so-called CAAX box) and this modification is important for membrane targeting and 
activation as evidenced by the fact that proteolytic cleavage of this site by Yersinia spp.-derived 
toxins effectively block Rho, Rac and CdC42 activation161.  Likewise, as RhoA is 
geranylgeranylated at this site, geranylgeranyl-transferase inhibitors and HMG-CoA-reductase 
inhibitors (which block both cholesterol and isoprenyl biogenesis) block RhoA membrane 
association and activation.  In fact the clinical utility of this approach is highlighted by the fact 
that HMG-CoA reductase inhibitors such as simvastatin and atorvastatin, used to treat high 
cholesterol, also have anti-hypertensive properties109 and their BP lowering effects have been 
attributed to their ability to block RhoA signaling108, 109, 164.  However, the BP lowering effects of 
statins are modest (2 mmHg decrease systolic BP) and these isoprenoid pathway inhibitors 
display poor selectivity for individual Rho GTPases.  Thus, further advancements in drug 
development are needed to realize the full potential of this approach.   
 
1.3.3  RhoA GEFs and blood pressure control 
Another potential strategy for inhibiting RhoA signaling is inhibition of the GEFs that 
control RhoA activity.  Over 24 Rho-specific GEFs have been identified, and to date, at least 5 of 
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these have been implicated in regulating SMC differentiation and/or contractility.  This list 
includes 3 members of the RGS-GEF subfamily (P115-RhoGEF, PDZ-RhoGEF, LARG), 
p63RhoGEF and lymphoid blast crisis (Lbc)20, 165-168.  Each of these RhoGEFs contains a Dbl 
homology (DH) domain (also known as the RhoGEF domain) followed by a pleckstrin 
homology (PH) domain (Table 1.2).  The DH domain serves as both the catalytic site and the 
major binding interface for RhoA, while the PH domain facilitates membrane binding and 
cooperates with DH domains to fully activate RhoA.  Other common domains include a regulator 
of G-protein signaling (RGS) domain that binds heterotrimeric G proteins, or the density 95, disk 
large, zona occludes-1 (PDZ) domain that binds to specific transmembrane receptors (including 
the Lysophosphatidic Acid (LPA) receptor among others169.  Importantly, these 5 GEFs are all 
highly expressed in conductance and resistance arteries of rats, mice, and humans20, 165-168 
(Genotype-Tissue Expression [GTEx] Portal, accessed on 07/12/2018).   
The regulator of G-protein signaling (RGS) family of Rho GEFs (LARG, p115RhoGEF, 
and PDZRhoGEF)170 has received a lot of attention in the BP field because these proteins are 
activated by Gα12 and Gα13- coupled receptors which transduce signals mediated by major 
contractile agonists that include AII, PE, ET1, and thromboxane A2171.  P115RhoGEF (p115) is 
the critical GEF that mediates AII-dependent RhoA activity in SMC and small arterioles, and 
importantly, Guilluy et al. showed that SM-specific deletion of p115 rendered mice resistant to 
AII-dependent HTN35.  However, AII–dependent activation of RhoA in SMC has also been 
linked to activation of LARG172, PDZ-RhoGEF165, 167, and p63RhoGAP173 and inhibition of 
p190RhoGAP174 (see below), suggesting significant overlap between these pathways.  For 
example, Ying et al. showed that Ca2+/PYK2-dependent activation of PDZ-RhoGEF was 
necessary for maximal A-II induced RhoA activation in SMC167.  Alternatively, p63-RhoGEF, 
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which is highly expressed in arterial SM, was shown to be important for the early phase of AII-
dependent vessel contractility173 and for maximal pressor response to other vasoconstrictors such 
as PE and ET1 that act through Gα q/11175.  Interestingly, p115 mutant mice exhibited normal 
pressor responses to ET1 and PE, but did not respond fully to AII and had a partial reduction in 
DOCA/salt- induced HTN.  On the other hand, LARG knockout mice were fully resistant to salt-
induced HTN20, which is consistent with subsequent findings that LARG regulates RhoA activity 
and SMC contractility in response to mechanical forces—which are known to be applied to small 
vessels in this volume overload model176.  While not yet confirmed in pre-clinical animal 
models, the non-RGS Rho GEF termed lymphoid blast crisis (Lbc) is necessary for serotonin-
dependent activation of RhoA and contractility in vascular SMC177.  Thus, specific 
vasoconstrictors can lead to activation of distinct but overlapping sets of RhoGEFs to enable the 
fine-tuning of vessel tone and BP homeostasis.  
With respect to pharmacological treatments, these findings indicate that targeting a 
critical SM GEF might provide greater therapeutic benefit than targeting RhoA or Rho kinase, 
because it could lead to a more modest (and cell type restricted) reduction of RhoA activity and 
result in fewer side effects.  Moreover, the use of validated inhibitors could provide 
‘personalized’ approaches that would better target the underlying pathophysiology (i.e. to limit 
HTN due to volume overload or elevated sympathetic activity).  On the other hand, known 
functional redundancies also suggest that it may be necessary to target multiple GEFs to achieve 




1.3.3a  Targeting RhoGEFs 
 GEF protein-dependent nucleotide exchange involves a multi-step reaction.  Upon 
binding to the GDP-bound form of the GTPase, GEFs facilitate release of GDP resulting in the 
formation of a nucleotide-free GTPase–GEF transition complex.  The reaction then terminates 
with the binding of GTP (which is in a 10:1 molar excess in the cell) and dissociation of the GEF 
from the now active GTPase.  The implication of this multi-step process for drug discovery is 
that these transition-binding intermediates tend to have the characteristics of druggable hotspots 
(i.e. exposed hydrophobic surfaces, unpaired polar groups, deeply curved surfaces, etc.) while 
the unbound, inactive proteins do not178.  Thus, it may be possible to identify small molecules 
that specifically target the GEF-GTPase interface (i.e. inhibit GEF binding or stabilize the GEF-
GTPase transition state) or directly interfere with GEF activity.   
 
1.3.3b  Targeting the RhoA-GEF interface 
 Facilitated by high resolution crystal structures and sophisticated in silico screening, 
some recent drug discovery approaches support the possibility of targeting the RhoA-GEF 
interface.  For example, Shang et al. virtually screened 4 million compounds for their ability to 
pack into the Rho-GEF binding surface groove of RhoA.  One of the drugs identified (termed 
Rhosin) contains two aromatic rings tethered by a linker which wraps around RhoA AA58 (a 
critical Tryptophan that is essential for GEF binding) and prevents RhoA from interacting with 
LARG, DBL, LBC, p115RhoGEF and PDZ RhoGEF without interfering with RhoGAP, 
RhoGDI, or RhoA effector binding151.  Rhosin reversibly inhibited serum-induced RhoA, RhoB 
and RhoC activity, but did not inhibit other Rho GTPases (Rac1 or Ccd42)151. Rhosin also 
significantly and dose-dependently inhibited several RhoA-dependent functions in cells 
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including MLC and PAK phosphorylation and stress fiber and focal adhesion formation151. 
Rhosin suppressed invasion and mammary sphere formation in breast cancer cells151, and also 
mitigated the acquisition of drug resistance in cancer stem cells179.  The ability of Rhosin to 
impact either BP homeostasis (or cancer growth) has not yet been tested in animal models.  Since 
Rhosin exhibits a relatively low binding affinity, (Kd ~0.4 µM for RhoA binding in vitro) the 
identification of derivatives with better pharmacologic properties will be needed before Rhosin 
compounds can be tested clinically151.  Moreover, since Rhosin binds to RhoA and prevents all 
GEFs from binding to this site, this drug is likely to have more off-target effects than one that 
could interfere with specific GEF complexes.   
The first proof-of-concept for targeting a specific GEF-GTPase interface was a series of 
elegant studies that unveiled the mechanism by which the fungal toxin, Brefeldin A (BFA), 
inhibited Arf1-dependent trafficking of proteins from the endoplasmic reticulum to the Golgi.  
Biochemical studies revealed that BFA selectively blocked the ability of the Arf1GEF, Sec7, 
from catalyzing GDP release.  Importantly co-crystallization studies revealed that BFA binds to a 
hydrophobic pocket that does not exist in Arf1GDP but is created upon Sec7 binding.  Since this 
energetically unfavorable hydrophobic pocket drives the conformational changes necessary for 
nucleotide dissociation, BFA binding effectively locks the complex in a GDP bound 
conformation180-182.  In spite of high sequence homology among the Arf1GEFs, only the Sec7 
complex is targeted by BFA, suggesting that ‘interfacial’ small molecule inhibitors could be 
identified that specifically target RhoA-GEF interactions. 
These studies have inspired a new line of investigation that seeks to exploit novel pockets 
at small GTPase-GEF interfaces.  The most productive approach so far used NMR-based 
fragment screening combined with high resolution structure/functional analyses to identify small 
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molecule inhibitors of kRas and its GEF, Sos1.  These screens identified compounds that either 
block Sos1 binding to kRAS or that bind to a site adjacent to the functionally important switch 
I/II regions of KRas and (like BFA) block SOS1-dependent nucleotide exchange. A similar 
approach was used to identify a ligand that binds to the cavity adjacent to the switch II region of 
RhoA and inhibits the interaction between RhoAGDP and the LARG DH domain183.  Small 
molecules have also been identified that inhibit TrioGEF's interaction with Rac1 and RhoG and 
Cdc42's interaction with the GEF, intersectin-1184.  Clearly much work needs to be done to 
realize the potential for such ligands.  The inhibitors identified exhibit very low potency (in the 
high micromolar range) and their ability to block additional GEFs has not yet been evaluated.  In 
fact, in silico evaluation of aforementioned SOS1 inhibitor suggests that the hydrogen bonds 
formed by this ligand in the Ras-SOS1 complex would likely be conserved in the complex of Ras 
and another cognate GEF, RasGRF1183.  While challenging, further medicinal chemistry and 
molecular dynamics approaches should facilitate our ability to target RhoA's interaction with 
specific GEFs.  
 
1.3.3c  Targeting GEF activity 
Another viable approach is to directly target the activity of specific RhoGEFs before they 
interact with the small GTPases. Using a high-throughput screen, Shang et al. identified a 
compound, Y16,  that binds LARG at the junction between the DH and PH domains with a Kd of 
~80nM185. Y16 prevented LARG from interacting with RhoA in vitro and reversibly attenuated 
serum-induced RhoA activity in NIH 3T3 cells and mammary sphere formation MCF7 cells with 
little to no toxicity185.  A separate fluorescent ligand-based screen of ten thousand compounds 
yielded five additional selective inhibitors of LARG-dependent RhoA GTPase activity, though 
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their mechanisms of action have not yet been determined186.  Again, to date, many of these lead 
compounds exhibit low potency, but theoretically, combination therapy strategies which pair 
Y16 with some of these compounds and/or their derivatives may lead to a highly efficacious 
approach to limit LARG-mediated signaling.   
 Finally, since many GEFs are regulated by protein-protein interactions and post-
translational modifications, it may be possible to identify drugs that block these mechanisms.  In 
an excellent example of this approach, cAMP is a potent activator of the Rap1 GEFs, Exchange 
Proteins directly Activated by cAMP (EPAC1 and 2) and high throughput screens to identify 
small molecules that displace cAMP binding led to the discovery of several inhibitors or partial 
agonists for these GEFs187-189.  Such studies support the concept that identification of small 
molecules that prevent physiological activation of specific GEFs could prove therapeutically 
useful. Along these lines, several studies have shown that RGSRhoGEFs are regulated by 
phosphorylation.  Guilluy et al. demonstrated that AII-dependent activation of p115GEF was 
mediated by phosphorylation of the PH domain (Tyr738) by Janus tyrosine kinase22. Importantly, 
phosphorylation mimetic and deficient variants of Tyr738 elevated and reduced p115's GEF 
activity, respectively.  PDZRhoGEF and LARG are also activated by tyrosine phosphorylation. 
Focal adhesion kinase (FAK) and its related family member, proline-rich tyrosine kinase 2 
(PYK2) phosphorylate and activate PDZRhoGEF167, 190, while FAK, Tec and the serine-
threonine kinase, p90 ribosomal kinase-2 each phosphorylate and activate LARG167, 170, 190, 191.  





1.3.4  RhoA GAPs and blood pressure control  
 Although GEFs have classically been considered to be the major regulators of 
RhoGTPase activity, increasing evidence suggest the GAPs are also critically important.  As 
their name implies, GAPs enhance the intrinsic GTPase activity of the Rho GTPases by several 
orders of magnitude thus decreasing the length of time that GTPases are in the active form192-194.  
The 66 RhoGAPs in the human genome comprise a broad and diverse family that can be further 
subdivided based upon the presence of a variety of functional domains195 (Table 1.3).  By 
mediating interactions with different membrane and protein components these domains are 
critical for the selective function of the GAP proteins and the dynamic inhibition of small 
GTPase signaling. Several Rho-selective GAPs including p190ARhoGAP, ArhGAP1, Myr5, 
GRAF1, and GRAF3 have been shown to inhibit RhoA activity in cultured vascular SMC and 
could be potential targets for therapeutic interventions that affect vascular function and BP36, 196.  
However, GRAF3 is the only RhoGAP that has been directly linked to the regulation of SM 
contractility and BP homeostasis15, 16, 36, 105, 106. 
 
1.3.4a  GRAF3 and Hypertension 
We originally identified the founding member of the GRAF (GTPase Regulator 
Associated with FAK) family by screening an embryonic λgt11 expression library for proteins 
that interacted with the carboxyl-terminal domain of FAK197-199.  This family which is now 
known to comprise 3 members, GRAF1 (ArhGAP26), GRAF2 (ArhGAP10) and GRAF3 
(ArhGAP42) contain an N-terminal BAR (Bin/amphiphysin/Rvs) domain, a phosphatidylserine 
(PS)-binding PH domain, a central Rho-GAP domain, a serine/proline rich domain, and a C-
terminal FAK-binding SH3 domain197.  GRAF1 is expressed predominantly in the brain and 
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striated muscle (cardiac and skeletal), and our studies in GRAF1-depleted Xenopus and mice 
revealed that GRAF1-dependent inhibition of RhoA activity promoted mammalian muscle 
growth by facilitating myoblast fusion and injury repair199-202.  GRAF2 is more ubiquitously 
expressed203 and could partially compensate for the loss of GRAF1 during myotube formation, 
supporting at least some functional redundancy within this family201. Evolutionarily, GRAF3 is 
the youngest family member and is the most recently annotated.  Importantly, we found that 
GRAF3 was highly and selectively expressed in SMC with particularly high expression in 
resistance vessels36 suggesting that its expression levels might be a major determinant of RhoA 
activity, SM contraction, and vessel tone.  
Over the last several years, studies from our laboratory confirmed that GRAF3 is a SMC-
selective Rho GAP protein that imparts tight control of BP homeostasis by modulating vascular 
resistance. Specifically, we showed that mice with gene-trap-mediated reductions in GRAF3 
levels exhibited significant basal HTN and elevated pressor responses to AII, ET1, PE, and 
DOCA salt36.  Notably, the hypertensive phenotype in this model was fully reversed by treatment 
with ROCK inhibitors or by Cre-mediated re-expression of GRAF3 in SMC, strongly supporting 
the contention that GRAF3 control of SMC RhoA activity is necessary for homeostatic control of 
basal and pressor-induced BP.  Mechanistically, our data supported a model wherein GRAF3 
controls BP homeostasis by limiting RhoA-dependent MLC phosphorylation and blunting acute 
Ca2+-mediated SMC contractility in resistance vessels. Moreover, depletion of endogenous 
GRAF3 from vascular SMC enhanced MRTF-A nuclear accumulation, and stimulated 
expression of contractile proteins including SM α-actin, SM-myosin heavy chain, calponin and 
SM-22, indicating that changing the levels of GRAF3 would likely have a long-lasting impact on 
vessel tone37.  Interestingly, GRAF3 mRNA was significantly upregulated in SMC cultures 
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subjected to cyclic stretch and in isolated portal vein segments subjected to static stretch and we 
showed that these effects were mediated via the RhoA/MRTF/SRF pathway37.  Since similar 
physical forces are known to be increased in the vessel wall under hypertensive conditions55, we 
postulated that GRAF3 might serve as a transcriptionally mediated negative feedback loop of the 
RhoA signaling axis.  In support of this possibility, arterial GRAF3 mRNA levels were 
significantly increased in mice made hypertensive by L-NAME or DOCA-salt regimens36.  In 
fact, taking advantage of an elegant mouse model (of aldosteronism) developed by the Smithies 
lab in which plasma volumes of mice range from ∼50% below normal to ∼50% above normal204, 
we showed that  GRAF3 expression increased in parallel to and was strongly correlated with 
plasma volume (r2=0.94)37.  Taken together, these findings suggested that GRAF3 serves as a 
mechanical strain-sensitive rheostat that acts to prevent excessive feed-forward activation of the 
RhoA signaling axis in order to control SMC tone and BP. 
Of clinical importance, three separate GWAS studies identified a blood-pressure 
associated allele within the GRAF3 locus. Notably, our recently published follow-up studies 
revealed that GRAF3 mRNA levels were approximately 3-fold higher in arteries from 
individuals homozygous for the protective allele and our human genetic data from well-
characterized untreated patients confirmed that the protective allele was associated with a 5mm 
Hg decrease in BP15, 16, 38, 106 (Appendix A and Appendix B).  We went on to identify a novel 
mechanism for the BP-associated locus which mapped to the first intron of the GRAF3 gene38. 
Our studies revealed that rs604723 is the causative SNP at this locus and that the minor T allele 
variation increases GRAF3 expression by promoting SRF binding to a SMC-selective intronic 
regulatory element.  Our demonstration that the minor GRAF3 allele is more highly expressed in 
human aortic SMCs (HuAoSMCs), when coupled with similar data from human artery samples, 
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strongly supports our hypothesis that this variation reduces BP by inhibiting RhoA-dependent 
constriction of resistance vessels. Our data add to a growing body of evidence that common 
noncoding variants alter cardiovascular risk by altering transcription factor binding and gene 
expression and support previous studies implicating RhoA signaling in the regulation of BP 
homeostasis in mice.  Moreover, when coupled with the remarkable SMC-selective expression 
pattern of GRAF3, these studies provide strong evidence for GRAF3 as a novel therapeutic 
target for HTN. 
 
1.3.4b  Druggability of RhoGAPs 
To date, targeting GAPs for therapeutic advances has been largely overlooked.  This is 
due, in part, because GAPs have little to no effect on promoting GTP hydrolysis of oncogenic 
Ras and Rho mutants, and therefore would not be good targets for cancer treatment205.  GAPs 
have also been considered less attractive targets for anti-hypertensive therapies because the drug 
would need to enhance GAP activity and it is traditionally thought to be more difficult to develop 
small molecule activators than small molecule inhibitors. Nonetheless, due to the multi-domain 
nature and the varied physiological regulation of RhoGAP proteins, there are several possibilities 
for allosteric modulation of GAP activity.  Indeed, the activities of several RhoGAPs including 
the GRAFs, OPHN1, β-chimerin, DLC1, and p50 Rho GAP are regulated by intramolecular 
auto-inhibition.  For GRAF1 and similarly structured Oligophrenin and ASAP1, the BAR and 
PH domains physically associate with the GAP domain to sterically inhibit its function206, 207.  
We and others have shown that this mechanism also controls the activity of GRAF3 (see Chapter 
2;208) (Figure 1.2).  By defining the structural interactions that control GRAF3 activity, these 
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results could lead to the development of GRAF3 activators that target the BAR-PH/GAP 
interface that should be useful for reducing arterial tone.  
 
1.4  Conclusions 
In conclusion, the search for new approaches to control high BP remains dramatically 
important for reducing global health burden, and targeting RhoA-mediated SM contractility is a 
promising avenue (Figure 1.3).  Indeed, strong evidence from pre-clinical animal models 
indicate that modulating the activity of SM Rho-GEFs, Rho-GAPs, or ROCK has a major impact 
on systemic BP homeostasis. While new advances in drug development have led to potent and 
specific ROCK inhibitors that can be safely used in patients, whether any of these compounds 
exhibit the necessary selectivity and pharmacological profiles required for BP management in 
patients requires further study.  Although efforts to target GEF and GAPs or the RhoA binding 
interface for these enzymes are lagging behind, recent advances in drug discovery indicate that it 
will likely soon be possible to engineer clinically-relevant small molecule regulators of these 
enzymes that could be effective anti-hypertensive therapies.  To ensure success in this regard, we 
will need to continue to gain a better understanding of the mechanisms that regulate these 
enzymes.  Moreover, based on the fact that BP is a highly variable trait among individuals, a 
better understanding of the genetic mechanisms regulating this disease is critical for a more 
personalized treatment plan for patients.  Given that genetic variations in both upstream 
activators and downstream mediators of RhoA have been linked to BP regulation, screening for 





1.5  Objectives  
 Due to the smooth-muscle specificity of GRAF3 and the regulation of RhoA signaling 
that GRAF3 exhibits in vitro and in vivo, the first major objective of this dissertation was to 
assess the therapeutic potential of GRAF3 activation/overexpression to reduce basal blood 
pressure or combat HTN.  The second objective of this work was to identify the biochemical 
mechanisms that regulate GRAF3 in SMCs.  Expanding our understanding of how GRAF3 
functions endogenously is pertinent for the screening and design of small molecule activators.  
More recently, our lab has discovered that in humans, GRAF2 is more highly expressed in SMCs 
than GRAF3 is.  The third and fourth objectives of this dissertation, therefore, respectively, were 
to better characterize the role of GRAF2 in BP homeostasis and to evaluate the degree of 







1.6  Figures 
 
Figure 1.1  RhoA pathway in smooth muscle cells. In addition to Ca2+-dependent activation of 
MLCK (not shown here), vasoconstrictors such as AII, PE, and ET-1 stimulate G-protein 
signaling in SMC via GPCRs.  G-proteins influence the activity of RhoA by activating GEFs, 
which facilitate the dissociation of GDP from RhoA, allowing GTP to bind.  This activation is 
balanced by GAPs, which increase the efficiency of GTP hydrolysis.  When RhoA is in its 
active, GTP-bound form, it’s able to interact with any of its downstream effectors, such as 
ROCK and mDia.  ROCK inhibits MLCP, allowing for prolonged phosphorylation of MLC and 
enhanced SMC contraction, increased vascular resistance, and increased blood pressure.  
Simultaneously, mDia and ROCK promote the polymerization of F-actin from G-actin, releasing 
G-actin bound MRTF. Free MRTF translocates to the nucleus where it induces SRF-dependent 
transcription of contractile genes.  The concurrency of these latter events further enhance SMC 





































































































































Table 1.2  Domain Structure of RhoGEF proteins associated with blood pressure.  The 
RhoGEF domain (also known as the Dbl homology [DH] domain), is the catalytically active 
domain of RhoGEFs  and major binding site for RhoA GTPase.  Immediately downstream of the 
RhoGEF domain is a pleckstrin homology (PH) domain, which works cooperatively with the 
RhoGEF domain to fully activate the RhoA GTPase.  Other functional domains in these 
RhoGEFs are the Regulators of G protein signaling homology (RH) domain and the postsynaptic 
density 95, disk large, zona occludens-1 (PDZ) domain. Potential blood pressure therapeutics are 
being developed to target the interaction interface between RhoGEF domain and RhoA.  Length 







Table 1.3  Domain Structure of RhoGAP proteins associated with blood pressure.  The GAP 
domain is the catalytically active domain of RhoGAPs.  GRAF3 also contains a 
Bin/amphiphysin/RVS (BAR) domain, a pleckstrin homology (PH) domain, and a SRC 
homology 3 (SH3) domain, which sense and induce membrane curvature, aid in lipid binding, 
and promote protein-protein interactions, respectively.  In addition to the catalytic GAP domain, 
p190-RhoGAP also contains a GTP-binding domain (GBD), four diphenylalanine motifs (FF), 
and a polybasic region (PBR).  These regions aid in GTP binding, assist in protein-protein 
binding, and allow for membrane association, respectively.  Potential blood pressure therapeutics 








Figure 1.2  Domain Structure and therapeutic strategy for targeting the SMC-specific 
RhoGAP GRAF3. Like other  BAR-PH-GAP containing proteins, the BAR and PH domains of 
GRAF3 act as a functional unit to autoinhibit the GAP domain, preventing GRAF3’s interaction 
with RhoA.  One potential therapeutic strategy is to use allosteric activation (either post-
translational modifications or small molecules, represented here by the purple star) to lock 
GRAF3 in its open conformation, enhancing hydrolysis of GTP to GDP, thereby decreasing the 






 Figure 1.3  Therapeutic potential of the RhoA pathway to treat HTN. There are many 
components of the  SMC RhoA contractile pathway that could be targeted to reduce systemic 
blood pressure.  While not an exhaustive list, shown here in bold boxes are compounds discussed 
in this article, including those that are proof-of-concept, in clinical development, or currently 




CHAPTER 2:  STRETCH ACTIVATION OF SRC AND FAK KINASES PHOSPHORYLATE 
GRAF3 AT Y376 IN VASCULAR SMOOTH MUSCLE CELLS TO PROMOTE 
RELAXATION AND LOWER BLOOD PRESSURE2 
 
2.1  Introduction 
 High blood pressure, known clinically as hypertension (HTN), is a highly prevalent and 
relevant disease in the Western world and is a major risk factor for myocardial infarction, stroke, 
and kidney failure.  It is estimated that 1 in every 3 adults in the US has HTN and another 1 in 3 
has prehypertension209.  Despite the wide-spread availability of antihypertensives, it is estimated 
that only half of medicated adults have their blood pressure (BP) under control210 .  One reason 
for this treatment insufficiency is the complexity of BP homeostasis.  Blood pressure regulation 
involves the integrated control of many different organ systems and the interplay of many 
genes24, 28.  One of the key components of HTN, however, is increased peripheral vascular 
resistance due to the contraction of vascular smooth muscle around arterioles24, 25, 27, 28.  Smooth 
muscle cell (SMC) contractility is enhanced by activation of the small GTPase RhoA, which 
plays a role in phosphorylation of myosin light chain (MLC), stress fiber formation, actin 
dynamics, and SMC gene expression29, 211, 212.  Because RhoA’s involvement in all of these 
processes, RhoA has been implicated in the development of HTN30, 125, 213. 
 Small GTPases such as RhoA are molecular switches, controlled by GEFs and GAPs.  
Guanine nucleotide exchange factors (GEFs) turn RhoA “on” by dissociating GDP so free GTP 
                                               
2 This chapter contains text, data, and figures being prepared for publication as an original research article and is co-
authored by Rachel A. Dee, Xue Bai, Christopher P. Mack, and Joan M. Taylor 
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can bind while GTPase activating proteins (GAPs) turn RhoA “off” by helping coordinate 
hydrolysis of GTP.  Our lab identified a smooth muscle-specific RhoA GAP protein, called 
GRAF3 (also known as ARHGAP42), that is capable of regulating vascular tone36-38, 214.  
GRAF3-deficient mice exhibit significant hypertension and increased pressor responses to 
Angiotensin II and endothelin 1; an effect that can be prevented by treatment with the Rho kinase 
inhibitor Y-2763236.  Both large and small arteries from GRAF3-deficient mice also exhibited 
increased contractility in vitro and in vivo36.  Recent GWAS and genetic studies have also 
identified a role for GRAF3 in BP regulation15, 16, 38 and recently, a family was identified with a 
translocation that results in truncated GRAF3215.  This haploinsufficiency of GRAF3 is 
associated with HTN and obesity215.  While there is a clear link between GRAF3 and BP 
homeostasis, the precise biochemical mechanism of how GRAF3 functions within SMCs is still 
unclear.  
 Recently, it was shown that phosphorylation of GRAF3 can cause migration changes and 
focal adhesion recruitment in fibroblasts208.  Because GRAF3 is only expressed endogenously in 
smooth muscle cells, it is necessary to determine its mechanism in this precise cell type.  The 
goal of this study was to identify molecular mechanisms of GRAF3 activity in vascular smooth 
muscle.  Herein we tested the ability for smooth-muscle specific GRAF3 overexpression to 
reduce basal BP in mice.   
 Importantly, we found that GRAF3 has an autoinhibitory mechanism of regulation 
where GRAF3’s BAR-PH domains regulate the activity of GRAF3’s GAP domain.  
Furthermore, we found that GRAF3 is phosphorylated by Src or FAK kinases at Y376 in vitro.  
We also found that this phosphorylation results in a decrease in pMLC in SMC, which may 
explain the decreases in blood pressure that GRAF3 overexpressing mice experience.  These 
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findings underscore the importance of GRAF3 in blood pressure regulation and lays the 
foundation for GRAF3 targeted antihypertensive therapies.  
 
2.2  Results 
2.2.1  Smooth muscle-specific GRAF3 overexpression decreases systolic blood pressure  
Previously, it has been shown that endogenous GRAF3 limits RhoA-dependent SMC 
tone and that its expression is necessary to maintain normal blood pressure homeostasis; GRAF3 
deficient mice exhibit a 25mmHg increase in blood pressure36.  Strong in vitro evidence also 
shows that ectopic expression of GRAF3 in Wt cultured SMC led to a marked reduction in SMC 
contractility as assessed by decreased actin polymerization and weakened connections between 
the cytoskeleton and extracellular matrix.  Thus, we sought to test the exciting possibility that 
elevated SMC-restricted GRAF3 overexpression will lower basal blood pressure and prevent 
HTN in mice with clinically relevant hypertensive disease.  
 To this end, we created a novel mouse model in which GRAF3 could be temporally and 
spatially controlled in a Cre-dependent fashion. Initially we overexpressed WT GRAF3 in the 
heart during development using constitutively active Nkx2.5 Cre, but this yielded no viable 
offspring (data not shown).  In accordance with other studies, we observed that limiting RhoA 
activity too much with WT GRAF3 overexpression in cell culture caused cell death216; therefore, 
we created a second Cre-inducible GRAF3 transgene (called GRAF3RQ) containing a mutated 
arginine (R417Q) that exhibits ~40% less GAP activity than WT.  To make GRAF3RQ 
overexpression smooth muscle specific, we crossed the GRAF3RQ mice to tamoxifen-inducible 
SM MHC CreERT2 mice (Figure 2.1A and 2.1B). 
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Using radiotelemetry, we observed blood pressure in 12-16 week old GRAF3RQ and 
GRAF3RQ SM MHC CreERT2 male mice.  Basally, both groups had an average systolic BP of 
about 125 mmHg (Figure 2.1C).  After tamoxifen injection and induction of GRAF3RQ 
overexpression in smooth muscle cells, basal blood pressure for the GRAF3RQ SM MHC CreERT2 
mice significantly decreased by about 10 mmHg compared to experimental controls (p<0.05) 
(Figure 2.1C).  While GRAF3RQ overexpressing mice were still amenable to BP increases when 
challenged with the hypertensive agonist L-NAME, importantly, GRAF3RQ overexpressing mice 
maintained the 10 mmHg decrease compared to their non-overexpressing counterparts (p<0.05 
for differences in BP each day between the GRAF3RQ overexpressing and non-overexpressing 
groups, p=0.1137 for the differences in the rate of rise of BP between the two groups) (Figure 
2.1C).  Diastolic BP, mean arterial pressure, and heart rate between the two groups did not vary 
significantly throughout the experiment (Supplemental Figure S2.1).  This finding supports the 
hypothesis that enhancing GRAF3 activity could be a novel effective therapeutic for HTN.    
 
2.2.2  GRAF3 displays autoinhibition of its GAP domain by its own BAR-PH domain 
  In order to assess the plausibility of a GRAF3 targeted therapeutic, it is necessary to 
understand the molecular mechanism of GRAF3 within SMCs. GRAF3 contains BAR, PH, 
GAP, and SH3 domains (Figure 2.2A), each of which may alter GRAF3’s subcellular location, 
cellular interactions, and function217, 218.  To better understand how these domains interact with 
one another, we used PyMol and ClusPro to build a predictive molecular model of GRAF3.  
Because the crystal structure of GRAF3 is currently unsolved, we used the BAR-PH domain 
from Appl1219 and the GAP domain from GRAF1220 to build our model.  Appl1 is a Rab5 
effector protein involved in cell proliferation and endosomal trafficking signaling pathways221, 222 
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while GRAF1, as mentioned previously, is the founding member of the GRAF family, involved 
in integrin and endocytic signaling223, 224.  The domains from these proteins were chosen because 
of their structural similarities to GRAF3 and their high conservation of functionally important or 
interface interacting residues.  The experimental structures of both Appl1 (BAR PH) and GRAF1 
(GAP) are available on the Research Collaboratory for Structural Bioinformatics (RCSB) Protein 
Data Bank (PDB) (www.rcsb.org)222.  We then performed a molecular docking search using 
ClusPro to dock GAP domains onto the BAR-PH domain dimer with a distance less than 30Å.  
Possible docking modes recovered 17 solutions that clustered into 2 groups of structures (Figure 
2.2B and 2.2C).  The structure on the top (Figure 2.2B) likely represents an open ‘active’ state 
because all of the residues important for GTPase binding and GAP activity (pink and dark blue, 
respectively) are exposed.  The structure on the bottom (Figure 2.2C) represents a closed, 
‘inactive’ conformation since the conserved face of the GAP domain (yellow) is lying on the 
BAR-PH domain (dark green and light green or dark purple and light purple) effectively masking 
the residues required for GTP hydrolysis.  Interestingly, the change in orientation of the GAP 
domain between the two dockings is a simple rotation about the horizontal axis by 90 degrees 
(note the different positions of the teal colored residues).  Importantly, our analysis suggests that 
the GAP domain interacts with the convex surface of the banana-shaped BAR dimer, a model 
consistent with biochemical evidence that the BAR domain of (similarly structured) oligophrenin 
simultaneously interacts with membranes, but through positive charged lysines that lie on the 
opposite concave surface206.  
Other BAR-PH-GAP-containing proteins such as oligiophrenin and GRAF1 display 
autoinhibition between the BAR-PH domain and GAP domain with high specificity206.  Our 
model supports the idea that the BAR-PH domain of GRAF3 could autoinhibit its own GAP 
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domain in a similar fashion.  To test this, we expressed full length Myc-GRAF3 in Rat Aortic 
SMCs (RaAoSMC) and saw attenuation of actin stress fiber formation, which is indicative of 
inhibition of RhoA, and therefore active GRAF3 (Figure 2.2D).  When we co-expressed excess 
Flag-GRAF3 BAR-PH alongside the full-length Myc-GRAF3, this effect was blocked, 
signifying more active RhoA (and thereby less active GRAF3); Accordingly, the excess GRAF3 
BAR-PH domain was able to inhibit the activity of the GAP domain of GRAF3 (Figure 2.2D 
and 2.2E).  
 
2.2.3  GRAF3 is phosphorylated at Y376 by Src and FAK kinases in vitro 
Our molecular model and NetPhos analysis predict that GRAF3’s autoinhibition could be 
controlled by a post-translational modification, such as phosphorylation, and may allow GRAF3 
to toggle between active and inactive (autoinhibited) states225, 226.  Src and Focal Adhesion 
Kinase (FAK) are two non-receptor tyrosine kinases we hypothesized could phosphorylate 
GRAF3 and cause this shift in activation.  Both Src and FAK are involved in outside-in cellular 
communication and are activated by mechanical stretch and integrin signaling25, 227-229.  Because 
of the continuous stretch and relaxation of the arteries as blood pumps through the body, vascular 
smooth muscle cells are consistently exposed to mechanical stretch and its concomitant signaling 
cascades.  It has been shown that signaling through Src and FAK not only affects Rho family 
activation230, but Src and FAK also interact with other members of the GRAF family (the 
founding member of the GRAF family, GRAF1, was named for its association with FAK; 
GTPase Regulator Associated with Focal Adhesion Kinase)197-200.  Previous large-scale 
phosphoproteomic studies identified tyrosine residues, 376 and 792, as potential phosphorylation 
sites by Src and FAK208, 231.  Our molecular model predicts that Y376 is on the outside of the 
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folded GRAF3 protein in the unstructured linker region between the PH and GAP domains 
(between the red and orange residues), a location that could be susceptible to phosphorylation 
(Figure 2.3A).  Tyrosine 792 is located in a proline/serine rich region just upstream of the SH3 
domain, which is not shown in our model.  
To test whether Src or FAK were capable of phosphorylating GRAF3 at these sites, we 
performed immunoprecipitation and radioactive kinase assay experiments.  Immunoprecipitation 
of Myc-tagged GRAF3 from Cos cells co-expressing Src or superFAK (a variant of FAK with 
increased catalytic activity232) show significantly decreased tyrosine phosphorylation when 
GRAF3 has a phospho-deficient mutation at Y376 (Y376F) (Figure 2.3B and 2.3C, 
respectively).  Phospho-deficient mutation of Y792 caused little change in phospho-tyrosine 
signal (Supplemental Figure 2.2), indicating that Y376 is the more dominant site of 
phosphorylation, thus we only focused on Y376 for the remainder of the study.  The importance 
of this site (Y376) was validated by probing immunoprecipitates with a phospho-specific 
GRAF3 Y376 antibody (Figure 2.3F and 2.3G).  Again, tyrosine phosphorylation was 
significantly decreased in cells containing the Y376F phospho-deficient variant of GRAF3 
(Figure 2.3F and 2.3G).  To ensure that phosphorylation of GRAF3 was caused by Src and FAK 
directly and not by an intermediary kinase within cells, we performed radioactive kinase assays, 
where purified GRAF3 BAR-PH-GAP or purified GRAF3 BAR-PH-GAP Y376F were 
incubated with active purified Src or FAK and ATP 𝛾P32.  Radioactive phosphates were 
incorporated into WT GRAF3 when incubated with either Src or FAK and this radioactive 
phosphate signal decreased when Src or FAK were incubated with GRAF3-BAR-PH-GAP 
Y376F (Figure 2.3D and 2.3E).  Therefore we concluded that both Src and FAK can 




2.2.4  Phosphorylation of GRAF3 at Y376 increases GAP activity and decreases RhoA activity in 
smooth muscle cells  
Until now, no one has shown the relevance and function of GRAF3 phosphorylation at 
Y376 in smooth muscle cells.  Our working model predicts that phosphorylation of GRAF3 at 
Y376 could cause a change in GAP activity.  Indeed, TR-FRET GAP assays showed that the 
phospho-mimetic GRAF3 Y376E has more GAP activity than WT GRAF3 and more rapidly 
converts GTP to GDP (Figure 2.4A, 2.4B, and 2.4C).  This increase in GAP activity is 
physiologically relevant in SMC. When RhoA signaling is downregulated, Rac and Cdc42 
signaling are upregulated, leading to increased lamellipodial formation and “arborization” of 
SMC.  Analyzing the cell morphology of RaAoSMC transfected with GRAF3 variants revealed 
that transfection of SMC with the Y376E variant decreases the percent of arborized cells 
compared to WT, while transfection of RaAoSMC with the Y376F phospho-deficient variant 
increases the percent of arborized cells compared to WT (Figure 2.4D and 2.4E).  RaAoSMC 
expressing a delta-BAR variant of GRAF3 had an even greater decrease in the amount of 
arborized cells compared to WT or the Y376E phosphor-mimetic, further supporting the 
autoinhibition mechanism of the GAP domain by the BAR-PH domains (Figure 2.4E).  
 
2.2.5  GRAF3 phosphorylation at Y376 prevents phosphorylation of myosin light chain in smooth 
muscle cells  
It’s important to understand how this altered GRAF3 and RhoA activity will effect 
downstream contraction of SMC in a physiologically relevant context.  Compared to SMC 
infected with GFP, RaAoSMC infected with Flag-GRAF3 lentivirus exhibited a decrease in 
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phosphorylation of myosin light-chain (pMLC), the major determinant of smooth muscle 
contraction (Figure 2.5).  Infection of SMC with Flag-GRAF3 Y376F resulted in a near-normal 
amounts of pMLC (Figure 2.5).   
 
2.3  Discussion 
Previously, we have shown that the smooth-muscle specific RhoA GAP protein GRAF3 
is involved in blood pressure homeostasis 36-38.  The current study further supports this by 
demonstrating that increased expression of GRAF3 in smooth muscle cells leads to decreased 
systolic blood pressure in mice and that increased activity of GRAF3 in SMCs caused by stretch 
leads to a decrease in pMLC via phosphorylation activation of GRAF3 at Y376 by Src and FAK 
(Figure 2.6).  
Excitingly, we found that GRAF3RQ overexpression in SMC could significantly reduce 
basal systolic BP in mice and maintain this difference through L-NAME induced HTN.  Albeit 
not tested in this study, this suggests that overexpressing GRAF3 after the development of HTN 
(which more accurately mimics human disease) would also effectively lower BP.  While L-
NAME recapitulates volume overload, a common characteristic in human HTN, it is of future 
interest to test the widespread ability of GRAF3 overexpression to prevent or reverse BP 
increases in other models of essential HTN that imitate different features also found in human 
HTN233.  As evidenced by the embryonic lethality of our mice constitutively overexpressing 
GRAF3 in their hearts and our observation that too much GRAF3 (and thereby too little RhoA 
activity) in cultured cells can lead to cell death, we conclude that there is a fine balance of 
GRAF3/RhoA activity required for survival and appropriate tone of SMCs in the vasculature.   
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While our data support Y376 as the main site of GRAF3 tyrosine phosphorylation, both 
our phospho-tyrosine immunoprecipitations and radioactive kinase assay data indicate that 
GRAF3 may be phosphorylated by Src and (more so by) FAK at other sites besides Y376.  This 
is corroborated by the PhoshoSitePlus database, which reports potential post-translational 
modifications of proteins from large mass-spectrometry studies (phosphosite.org).  Tyrosines 
376  and 792 were identified as sites of post-translational phosphorylation in over 200 and 600 
independent studies, respectively, however at least 2 other tyrosines were identified in at least 1 
study each and 19 other residues were identified as potential sites of phosphorylation231.  While 
both Y76 and 792 are conserved between multiple species231, we show that Y376, located 
between the PH and GAP domains can control GAP function of GRAF3.  Tyrosine 792 is 
located in the proline/serine rich region a short ways upstream of the SH3 domain 
(Supplemental Figure S2.2), and thus more likely affects activities of GRAF3’s SH3 domain, 
such as intracellular localization and protein-protein interactions, though we did not test this in 
our current study208. 
Previously, we’ve shown that GRAF3 depletion affects pMLC and contraction in vivo.  
GRAF3-deficient mice had more pMLC staining in SMC-heavy tissues such as the stomach, than 
their WT counterparts36.  In this study, we saw a decrease in pMLC in SMC that overexpress 
activated GRAF3 in vitro.  It will be important to determine if the levels of GRAF3 pY376 
activation occur in vivo, in tissue samples from animals subjected to hypertension or ex vivo from 
isolated muscle segments subjected to stretch. 
Arteries are continuously exposed to pulsatile pressure as blood flows throughout the 
body after every heartbeat.  To protect blood vessels from injury, vascular SMC have an intrinsic 
myogenic response, contracting when there is an increase in pressure and dilating when there is a 
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decrease in pressure.  Detecting and transducing these mechanical signals, therefore, is a key 
signaling mechanism for vascular SMC and we postulate that the GRAF3 activation mechanism 
discovered in this study is part of a mechanotransduction feedback loop to keep RhoA activity 
and SMC contractility constrained.  
Mechanical stretch signals activate ion gated channels, cell adhesion molecule proteins, 
and integrins on the surface of SMCs which lead to upregulation of the PI3K, ERK, and RhoA 
pathways to control cell proliferation, survival, motility and migration, and contractility.  These 
pathways lead to the Ca2+-calmodulin dependent phosphorylation of myosin light chain kinase, 
which phosphorylates myosin light chain (MLC), allowing MLC to interact with actin and form 
cross-bridges and initiate contraction. Simultaneously, these pathways activate RhoA, which 
stimulates Rho kinase (ROCK).  ROCK inhibition of myosin light chain phosphatase further 
enhances contraction of SMCs.  RhoA also promotes the polymerization of F-actin from G-actin, 
releasing G-actin bound myocardin related transcription factors (MRTFs) that bind to serum 
response factor (SRF), translocate to the nucleus, and promote transcription of SMC contractile 
genes such as myosin heavy chain, SM22, calponin, and SM alpha-actin. The MRTF/SRF 
localization to the nucleus also increases the expression of GRAF337, in a feedback loop to level 
off RhoA activity and keep contractile gene expression within a certain range37.  We postulate 
that stretch-induced integrin activation of FAK and Src feed into this loop, by phosphorylating 
GRAF3 at Y376, thereby activating existing and freshly transcribed GRAF3 to reduce RhoA 
activity, and restrict contractile gene expression to within a certain range.  
This feedback loop and contractile protein level stabilization is paramount to the 
phenotypic modulation of SMC.  Smooth muscle cells do not terminally differentiate; they retain 
remarkable plasticity and can switch between a contractile phenotype and a proliferative 
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phenotype, depending on the level of contractile gene expression. Enhancement of the contractile 
phenotype leads to stiffening of SMC and large artery stiffening.  Preclinical studies have 
suggested that arterial stiffening is a precursor to HTN and other CVD outcomes234, but there are 
no approved therapies that directly target arterial stiffening.  Studies in spontaneously HTN rats 
have also linked the ROCK/SRF/MRTF pathway to control of arterial stiffening.  Therefore, 
long-term activation of GRAF3 and dampening of SMC contractile gene profiles could help 
prevent arterial stiffening and significantly slow the progression of HTN, especially in ageing 
populations that are prone to arteriosclerosis. 
In conclusion, HTN is one of the leading global health risks235, but the complexity of BP 
homeostasis makes HTN a difficult disease to treat.  Our study provides a mechanistic link 
between phosphorylation of GRAF3 at Y376 and the relaxation of SMC, leading to decreased 
BP and we argue this could also contribute to the prevention of arterial stiffening.  Our findings 
therefore support the development of novel GRAF3-targeted therapies to treat HTN and CVD.   
 
2.4  Materials And Methods 
 
Generation and characterization of GRAF3RQ SMMHC-CreERT2 mice 
Chimeric mice were produced in-house by injection of GRAF3RQ ES cells into the blastocoel 
cavity of mouse blastocysts by standard procedures.  The GRAF3RQ strain was established 
using two independent chimeras that demonstrated germline transmission when bred to wild-
type C57bl6 mice. GRAF3RQ SMMHC-CreERT2 mice were generated by crossing GRAF3RQ 
female mice with SMMHC-CreERT2 male mice.  All experiments were performed using age 
and sex-matched genetic controls.  Only male mice were used in this study because the 
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SMMHC-CreERT2 is located on the Y chromosome.  Genotyping was performed using DNA 
isolated from tail biopsies using locus-specific primers (for GRAF3RQ: 5′- 
gttcggcttctggcgtgtgac; 3′- ggtccctcgaagaggttcactag, for SMMHC-CreERT2: 5’-
tgaccccatctcttcactcc; 5’-aactccacgaccacctcatc; 3’-agtccctcacatcctcaggtt).  Overexpression was 
assessed by comparing levels of myc-tagged GRAF3 in organ lysates from tamoxifen 
(100mg/kg for 3 days via oral gavage) or non-tamoxifen treated animals.  Animal husbandry 
was provided by staff within the University of North Carolina Division of Comparative 
Medicine and all animal procedures were approved by our accredited American Association 
for Accreditation of Laboratory Animal Care committee and the Institutional Animal Care and 
Use Committee.  
 
Blood Pressure Measurements 
Conscious blood pressure was measured in male mice aged 12–16 weeks using radiotelemetry 
(Data Sciences International).  Implantable mouse BP transmitters (PA-C10) were used to 
record arterial pressure in conscious and freely moving mice.  In brief, the mice were 
anaesthetized with 2% isoflurane, the telemetry catheter was inserted into the left carotid 
artery of the mouse and the catheter tip was advanced into the thoracic aorta.  The catheter 
was fixed in the left carotid artery and the transmitter was inserted subcutaneously along the 
right flank.  Mice were allowed 7 days of recovery following transmitter implantation and 
were housed individually in a standard polypropylene cage placed on a radio receiver.  
Following baseline readings, mice were treated with tamoxifen (100mg/kg) for 3 consecutive 
days via oral gavage.  Increasing doses of Nω-Nitro-L-arginine methyl ester hydrochloride 
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(L-NAME salt) (50mg/L, 150mg/L, 450mg/L) were added to drinking water for 7 days (per 
dose). Mice were maintained in a 12:12-h light–dark cycle.  All blood pressure parameters 
were telemetrically recorded and stored with the Ponemah data acquisition system (Data 
Sciences International).  Recordings were collected for 5 minutes every 30 minutes 
throughout the study and averaged over a 24 hour period for each day.  
 
Cell culture and transfection 
Cos cells and RaAoSMC were maintained in DMEM or DMEM-F12 media, respectively, 
supplemented with 10% fetal bovine serum and 0.5% penicillin/streptomycin.  Cells were 
transfected with plasmids using Trans-IT (Mirus Bio) transfection reagents according to 
manufacturer’s protocol.  Myc-GRAF3 was made by cloning into a pCMV-Myc vector 
(Clonetech).  Flag-GRAF3 Bar-PH was made by cloning into a pcDNA3 vector.  GST-GRAF3-
BAR-PH-GAP was made by in-fusion cloning (Clonetech) into a pGEX6.1 vector (GE).  All 




Molecular models of GRAF3 were built using PyMol to combine the BAR-PH domains of Appl1 
(PDB ID 2Q13, Human Appl1) and the GAP domain of GRAF1(PDB ID 1F7C, chicken 
GRAF1).  The domains from these proteins were chosen because they were the most similar and 
highly conserved proteins/domains (compared to GRAF3) that had solved experimental 
structures available on the Research Collaboratory for Structural Bioinformatics (RCSB) Protein 
Data Bank (PDB) (www.rcsb.org).  The GAP domain was then docked onto the BAR-PH 
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domain using the Clus Pro protein-protein docking server236-238.  Models were narrowed down by 
analyzing the location and plausibility of residues important for GTPase binding and hydrolysis.  
 
Western blotting 
Cells were lysed in RIPA buffer + 0.5% Triton with protease and phosphatase inhibitors.  Protein 
concentration was determined by using a colorimetric BCA assay (Pierce).  Lysates were 
electrophoresed on 10-15% SDS-PAGE gels, transferred to PVDF membrane and 
immunoblotted with specific antibodies as indicated using a 1:1000 dilution.  Myc, Src, pMLC, 
MLC, and Arhgap42 pY376 antibodies were from Cell Signaling; Flag antibody from Sigma; 
pTyr antibody from EMD Milipore; GAPDH from Novus Biologicals; GFP antibody from 
Meridian Life Sciences.  Blots were washed in TBST (TBS plus 0.05% Triton X), followed by 
incubation with horseradish peroxidase conjugated secondary antibodies (Amersham) at a 




Cos cells were transfected with myc-GRAF3 variants and either Src or Flag-superFAK plasmid 
constructs.  After 24 hours, cells were lysed with RIPA buffer + 0.5% Triton and myc-tagged 
GRAF3 was immunoprecipitated overnight from cell lysate using a myc antibody (Cell 
Signaling) conjugated to Dynabeads Protein G (Invitrogen).  Immunoprecipitates and lysates 






GST-GRAF3 constructs were transformed into BL-21 competent E. coli and expressed by IPTG 
induction at 16°C overnight.  E.coli were lysed with a lysozyme-buffer (20mM HEPES, 150mM 
NaCl, 5mL MgCl2, 1% Triton X-100, 1mM DTT, 5mg/mL lysozyme, protease inhibitors), 
sonicated, and then protein was purified using glutathione-sepharose beads (GE Life Sciences).  
For GAP assay, constructs were dissociated from beads via reduced glutathione and GST was 
removed via PreScission Protease (GE LifeSciences) according to manufacturer’s protocol.  
 
Radioactive In Vitro Kinase assay 
Purified GST-GRAF3-BAR-PH-GAP or GST-GRAF3 BAR-PH-GAP-Y376F were incubated in 
kinase buffer (25mM MOPS, 25mM MgCl2, 5mM EGTA, 2mM EDTA, 12.5mM β-glycero-
phosphate, 2.5 mM DTT) with either active FAK (R&D Systems) or Src (Sigma) kinase and 
radioactive gP32 (Perkin Elmer) at 30°C for 15 minutes.  Reaction mixture was run on a 10% 
SDS-PAGE gel, gel was dried, and phosphorylation was assessed by radiograph.  Gel was 
rehydrated and stained with Coomassie Blue to assess total protein concentration.    
 
TR-FRET GAP assay 
The GAP activity of the GRAF3 BAR-PH-GAP proteins were measured using the Transcreener 
Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET) GDP assay kit (BellBrook 
Labs).  Briefly, various concentrations of purified WT or Y376E mutated GST-GRAF3 BAR-
PH-GAP were combined with RhoA , GTP, and GDP HiLyte647 tracer (bound to a GDP 
antibody conjugated to terbium) as per manufacturer’s instructions.  Amount of FRET signal was 
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measured over 140 minutes on a CLARIOstar (BMG Labtech) plate  reader 
(Ex320/Em615/Em665).   
 
Morphology Assay 
RaAoSMC were transfected with myc-GRAF3 variants for 24hours, fixed in 4% PFA, 
permeabilized with 0.5% Triton X-100 and stained with 1:500 myc (Cell Signaling) and 1:500 
Alexaflour 488 Goat anti-mouse (Invitrogen) antibodies.  Thirty 20x image tiles were taken on 
an Olympus IX81 microscope and then stitched together in Image J software.  Transfected cells 
of each morphology type were counted using the Image J cell counter.  
 
Lentiviral Infection 
GFP and Flag-GRAF3 (WT or phosphomimetic and phosphodeficient variants) lentiviruses were 
generated by transient transfection of HEK293T cells with a lentiviral vector together with a 
packaging plasmid and an envelope plasmid (PSPAX2 and PMD2G).  The supernatant 
containing lentiviruses was collected, incubated with a 40% PEG solution O/N, and then filtered 
through a 0.45µM sodium acetate filter, and stored in aliquots at -80°C.  RaAoSMC were 
infected with GFP or Flag-GRAF3 lentivirus with the aid of Polybrene (Sigma).  After 48 hours, 
cells were lysed in 2X Laemmli sample buffer, and subjected to Western Blotting.  
 
Statistics 
All data represent at least three individual experiments and are presented as means ± standard 
deviation.  Means were compared by Student’s t-test or linear regression (where indicated) 
and statistical significance is reported as p-values.  Sample sizes were chosen based on an 
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extensive literature search and standard exclusion criterion of two standard deviations from 
the mean were applied.  Band intensities were quantified using ImageJ software.  All statistics 




2.5  Figures 
 
Figure 2.1  SMC-specific GRAF3RQ overexpression decreases basal systolic blood pressure 
and maintains decrease through L-NAME dependent hypertension.  (A) schematic of 
GRAF3RQ stop and go transgenic construct and tamoxifen-inducible SM MHC-MHC-CreERT2 
construct used for SMC-specific GRAF3 overexpression mouse experiment. (B) Western 
analysis of Cos cells transfected with the GRAF3RQ plasmid and infected with Cre or LacZ 
control virus. Data is representative of 3 independent experiments. (C) Average 24 hour systolic 
blood pressure, measured via radio-telemetry, of unrestrained, conscious GRAF3RQ and 
GRAF3RQ SM MHC-CreERT2 mice before and after tamoxifen treatment (100mg/kg for 3 
consecutive days) and increasing L-NAME doses (50mg/L, 150mg/L, or 450mg/L) given for a 
week (each) in drinking water.  Data are expressed as mean ± SD; n=4 for GRAF3RQ  mice and 
n=3 for GRAF3RQ SM MHC-CreERT2.*p>0.05 vs. GRAF3RQ (Student’s t-test). Linear 






Figure 2.2  BAR-PH mediated autoinhibition of GRAF3.  (A) Schematic of GRAF3 domain 
structure. Structures of the GRAF3 BAR-PH-GAP dimer were created using Pymol and the 
solved, similar structures of Appl1 (BAR-PH) and GRAF1 (GAP). ClusPro docking simulations 
predicted 2 conformations for GRAF3: an (B) open and active or (C) closed and auto-inhibited. 
Color scheme follows: BAR 1 (dark purple), PH 1 (light purple), BAR 2 (dark green), PH 2 
(light green), GAP 1 and 2 (yellow), arginine fingers (active site) (dark blue), RhoA docking 
sites (pink), C-terminus of PH domain (red), N-terminus of GAP domain (orange); residues in 
teal aids in visualizing rotation. (D) Immunofluorescent staining of RaAoSMCs transfected with 
Myc-GRAF3 alone or Myc-GRAF3 co-expressed with Flag-BAR-PH (BPH) domain. Arrows 
point to phalloidin-stained cells of interest that are positive for Myc- (green) and/or Flag- (red) 
staining. (E) Schematics of GRAF3 in open, active, or autoinhibited, inactive conformations, 








Figure 2.3  Src and FAK kinases phosphorylate GRAF3 at Y376 in vitro (previous page).  
(A) Location of Y376 on GRAF3 schematic indicated by circle between PH and GAP domains. 
On the 3D model, arrow indicates approximate location, in the unstructured, unmodeled linker 
between the C-terminus of the PH domain (red) and the N-terminus of the GAP domain (orange). 
Cos cells were transfected with the indicated Myc-GRAF3 variant and either (B) Src or (C) 
superFAK. Myc-tagged GRAF3 was immunoprecipitated from cell lysate and blots were probed 
for tyrosine phosphorylation, as well as myc, Src or Flag, and GAPDH as controls.  Purified 
GRAF3 BAR-PH-GAP (BPG) domain and GRAF3 BAR-PH-GAP Y376 were subjected to a 
radioactive kinase assay using activated (D) Src or (E) FAK and ATP γP32.  Phosphorylated and 
total GRAF3 are shown by radiograph (top) or Coomassie Blue staining (bottom), respectively. 
Cos cells were transfected with the indicated Myc-GRAF3 variant and either (F) Src or (G) 
superFAK. Myc-tagged GRAF3 was immunoprecipitated from cell lysate and blots were probed 





Figure 2.4  Phosphorylation of GRAF3 at Y376 increases GAP activity in vitro and 
decreases RhoA activity in SMC.  TR-FRET GDP assay was performed using (A) 10nM, (B) 
30nM, and (C) 100nM purified WT or Y376E mutated GRAF3 BAR-PH-GAP. A decrease in 
signal indicates an increase in GTP to GDP conversion. (D) RaAoSMC were transfected with the 
indicated Myc-GRAF3 variants and stained with Myc and anti-mouse antibodies. Cell 
morphology of positive cells were classified as normal, transitional, or arborized as a readout of 
RhoA activity. (E) Percent cells in each category were compared between variants. n=150-200 





Figure 2.5  GRAF3 phosphorylation at Y376 decreases pMLC in SMC. Representative 
Western analysis of pMLC in RaAoSMC infected with GFP or Flag-GRAF3 lentivirus variants. 






Figure 2.6  Working model of GRAF3 activation.  Mechanical signals outside the cell activate 
integrins along the cell membrane.  Integrin signaling in turn activates Src and FAK kinases 
which phosphorylate GRAF3 at Y376.  Phosphorylation at Y376 causes a conformational shift 








2.6  Supplemental Figures 
 
Supplemental Figure S2.1  SMC-specific GRAF3RQ overexpression has no effect on 
diastolic BP, MAP, or HR. Average 24hr (A) diastolic BP (B) MAP, and (C) HR measured via 
radio-telemetry, of unrestrained, conscious GRAF3RQ and GRAF3RQ SM MHC-CreERT2 mice 
after tamoxifen treatment (100mg/kg for 3 consecutive days) and increasing L-NAME doses 
(50mg/L, 150mg/L, or 450mg/L) given for a week (each) in drinking water.  Data are expressed 
as mean ± SD; n=4 for GRAF3RQ mice and n=3 for GRAF3RQ SM MHC-CreERT2.*p>0.05 




Supplemental Figure S2.2  Phosphorylation of GRAF3 by Src and FAK occurs at Y376 
(predominant) and Y792 (to a lesser degree). (A) Schematic of GRAF3 domain structure; 
location of Y376  and Y792 indicated with circles.  Cos cells were transfected with the indicated 
GRAF3 variant and either (B) Src or (C) superFAK. Myc-tagged GRAF3 was 
immunoprecipitated from cell lysate and probed for tyrosine phosphorylation. Data is 







CHAPTER 3: CONTRIBUTION OF GRAF2 TO BLOOD PRESSURE REGULATION AND 
ARTERIAL STIFFNESS3 
 
3.1  Introduction 
Although HTN is an important risk factor for cardiovascular disease, the precise 
mechanisms by which it exerts detrimental effects on the cardiovascular system are still unclear.  
Recent studies have implicated artery stiffness in the pathology of HTN and this parameter has 
been shown to be a valuable predictor of end organ failure239-243.  Decreased vessel compliance 
elevates the mechanical load on the myocardium but also increases peripheral pulse-pressure in 
the microvasculature resulting in tissue damage in high flow organs such as the brain and 
kidneys.  It is thought that the activation of endothelial cells (EC) and SMC by increased vessel 
wall stress is an early event that leads to vessel remodeling and atherogenesis244-246.  In fact it is 
now recognized that increased vascular stiffness during aging or the development of HTN results 
from changes in the intrinsic mechanical properties of vSMC247, 248, in addition to changes in the 
composition of the vessel’s extracellular matrix (i.e. an increased ratio of collagen to elastin).  
 Previously, our lab found that the RhoA GAP protein GRAF3 plays a role in BP 
homeostasis, regulating expression of contractile genes and serving as a pressure-sensitive 
rheostat in SMC. During our qPCR-based examination of GRAF family member expression in 
the mouse, however, we noticed that message levels for GRAF2 (the GRAF family member most 
homologous to GRAF3) were qualitatively higher than GRAF3 in nearly all SMC-containing 
                                               
3 This chapter contains text, data, and figures being prepared for publication as an original research article and is co-
authored by Rachel A. Dee, Xue Bai, Christopher P. Mack, and Joan M. Taylor 
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tissues.  According to the GTEx database, expression of GRAF2 in human SMC tissues is not 
only higher than GRAF3 (approximately 10 fold in arteries) but surprisingly more SMC-
selective (Figure 3.1). 
GRAF2 (also known as PSGAP or Arhgap104) is the 2nd identified member of the GRAF 
family of BAR-PH-GAP proteins known to regulate RhoA and (to a lesser degree) CDC42 in 
vitro and in vivo 249.  Over expression of GRAF2 in fibroblasts results in reorganization of 
cytoskeletal structures and changes in cellular morphology.  GRAF2 is essential for Proline-rich 
tyrosine kinase 2 (PTK2) regulation of cytoskeletal organization 249.  Like other members of the 
GRAF family, GRAF2 interacts with focal adhesion kinase (FAK).  Because of all these 
similarities, we hypothesized that GRAF2 may also play a role in BP and vessel tone regulation 
like GRAF3 does.   
The goal of this study was to explore the function of GRAF2 in SMC and its role in blood 
pressure homeostasis and arterial stiffening.  We have found that global GRAF2 depletion results 
in significant elevation of BP and an increase in SMC contractile gene expression and collagens 
associated with CVD.  This may explain why smooth muscle-specific knockout mice display an 
increase in pulse wave velocity (PWV) (data not shown).  These results may lead to anti-
hypertensive therapies that can achieve benefits that protect against HTN as well as other 
manifestations of CVD.    
 
 
                                               
4 sometimes Arhgap10 is also used interchangeably with Arhgap21, especially in the cancer field but GRAF2 and 
arhgap21 are NOT the same protein.  GRAF2 has a Bar, PH, GAP and SH3 domain, while Arhgap21 has a PDZ, 
PH, and GAP domain. 
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3.2  Results 
 
3.2.1  GRAF2 is strongly and selectively expressed in SMC 
To explore GRAF2’s role in regulating vessel tone and blood pressure homoeostasis in 
vivo, we generated a GRAF2-depleted mouse line using a “knockout first” approach (Figure 
3.2), using ES cells that contained an inhibitory LacZ gene trap within the GRAF2 seventh 
intron (Figure 3.2).  Crosses between GRAF2+/gt mice yielded offspring in the appropriate 
Mendelian ratios.  Western Blot analysis of bladders from GRAF2gt/gt mice showed a 90+% 
reduction of GRAF2 protein (Figure 3.3B).  Inclusion of the LacZ/neo insertion cassette into 
the GRAF2 transcript results in a heterologous protein that contains GRAF2 amino acids 1-
234 fused in frame to the β-Gal reporter gene allowed us to visualize GRAF2 expression in 
various mouse tissues.  As expected, β-Gal staining in gene trap mice closely mimicked 
endogenous GRAF2 expression with strong staining in the aorta, liver, lung, mesentery, and 
bladder, and lack of GRAF2 expression in the brain (Figure 3.3A).  High power images of the 
lung co-stained with β-Gal and SM-alpha actin antibodies revealed that expression was 
restricted to SMC. 
 
3.2.2  GRAF2 depletion elevates blood pressure 
To test whether GRAF2 also contributed to BP homeostasis we measured basal blood 
pressures in our GRAF2gt/gt mice.  Tail cuff measurements revealed an 18 mmHg increase in 
basal systolic BP and similar increases in diastolic pressure and MAP (13 mmHg and 15 mmHg, 
respectively; p<0.05; n=3 for Wt, n=5 for GRAF2gt/gt) (Figure 3.4).  There was no significant 
difference in heart rate between the two groups.  To test whether GRAF2 from smooth muscle 
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cells, specifically, is the cause for this effect, we created tamoxifen-inducible, smooth muscle-
specific GRAF2 knockout mice.  Starting with the “knockout first” mouse, we crossed them to 
flippase (Flp) recombinase mice to remove the lacZ cassette, restoring GRAF2 to normal, but 
leaving exon 8 flanked by loxP sites.  We then crossed these GRAF2flox/flox mice with tamoxifen 
inducible SM MHC-CreERT2 mice.  Tamoxifen treatment results in a significant decrease of 
GRAF2 expressed in tissues (Figure 3.3C).  
 
2.2.3  GRAF2 expression is increased in mice with HTN  
 Previously, we’ve found that GRAF3 expression is increased with HTN in mice as part of 
a pressure-sensing feedback mechanism to try to keep BP under control.  GRAF2 may be 
involved in a similar feedback mechanism; PCR analysis of  aortas from L-NAME treated mice 
and renin transgenic hypertensive mice showed significantly higher amounts of GRAF2 
compared to untreated, WT mice (Figure 3.5E).   
 
3.2.4  GRAF2 depletion causes an increase in expression of SMC contractile genes and 
collagens, increasing vessel stiffness  
Similar to what we have observed with GRAF3, ectopic expression of GRAF2 markedly 
attenuated RhoA-dependent actin stress fiber and focal adhesion formation  in SMC (Figure 
3.5A).  Conversely, siRNA-mediated depletion of GRAF2 in human AoSMC led to a 
significantly higher expression SMC contractile genes such as myosin heavy chain (MHC), 
smooth muscle alpha actin (SMA), and calponin (CNN) (Figure 3.5B and 3.5C). GRAF2 
depletion in rat aortic SMC also led to an upregulation in MHC, SMA, and CNN, albeit much 
less dramatically.  Interestingly, siRNA knockdown of GRAF2 in RaAoSMC also dramatically 
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augmented synthesis of collagens Col3a1, Col4a1, and Col8a1 (Figure 3.5D).  These collagens 
were also significantly augmented in bladders isolated from GRAF2fl/fl SM MHC-CreERT2 mice 9 
days after being treated with tamoxifen (Figure 3.5F).  This a highly significant finding given 
the fact that the collagen to elastin ratio is a major determinant of arterial compliance and 
because polymorphisms in Col4a1 and Col8a1 have been shown to impacted pulse wave velocity 
(PWV) and because monogenic mutations in Col3a1 and Col4a1 have been associated with 
aneurisms250.  Furthermore, we found that PWV of GRAF2gt/gt mice was significantly elevated 
(Figure 3.5G).  Thus, GRAF2 regulates SMC contractility and vessel stiffness.  
 
3.3  Discussion 
Decreased vessel compliance is currently used as a predictive biomarker of ageing and 
CVD251-253.  Under normal conditions, pulse pressure expands the arteries and transfers energy to 
the arterial wall, resulting in a deceleration of pulse velocity as blood travels the body.  When 
arteries have stiffened however, they cannot expand as much and cannot accept as much energy 
transfer.  This excess energy is unfortunately unloaded onto the vessels of the microcirculation, 
leading to end organ damage254, therefore increased PWV has been associated with a greater risk 
of CVD, independent of BP255.  Because GRAF2 is abundantly and selectively expressed in 
human SMC and plays a non-redundant role in BP regulation, it is important to further assess the 
relative SMC-specific contributions of GRAF 2 to vessel tone and BP homeostasis.  
We and others have shown that RhoA activation promotes a robust positive 
transcriptional feedback circuit that activates a cellular “stiffness” gene program that includes 
integrin and RhoGTPase signaling molecules, cytoskeletal and contractile proteins as well as 
many of the transcription factors that drive expression of these genes (e.g. SRF and the 
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Myocardin factors)256.  Based upon our current findings, we hypothesize that SMC-selective 
expression of GRAF2 limits vessel stiffening by dampening this robust feed-forward signaling-
transcription circuit. As noted above siRNA-mediated depletion of GRAF2 in cultured SMC 
induced a number of changes that enhance intrinsic cellular stiffness including an increase in the 
size and number of focal adhesions and increases in the expression of SMMHC, SM α-actin, and 
calponin.  Moreover, since we have shown that GRAF2-depletion promoted gene expression 
programs in SMC that increase both cellular and extracellular matrix (ECM) stiffness, we 
hypothesize that GRAF2, like GRAF3, act to limit age-dependent arterial stiffness and its 
detrimental effects on cardiovascular function. 
Our findings that homozygous GRAF2 gene trap mice are hypertensive (+18 mm Hg) 
and that collagen expression was upregulated in GRAF2-deficient cells and the GRAF2 SM-
specific mice within just 1 week following tamoxifen treatment provides strong support for our 
postulate that SMC-GRAF2 depletion will induce HTN and aberrant vascular stiffness.  Thus, 
we are poised to better understand the contributions of vascular stiffness to vessel remodeling, 
rarefaction, and target organ damage and our results will have important implications for 
targeting of anti-hypertensive therapy to achieve benefits beyond lowering BP.  
 
3.4  Materials and Methods 
 
Generation and characterization of GRAF2 depleted  mice 
GRAF2  “knockout-first” gene trap ES cells were developed and distributed by the European 
Mouse Mutant Cell Repository (EuMMCR; Munich, Germany).  Chimeric mice were 
produced in-house by injection of GRAF2+/gt  ES cells into the blastocoel cavity of mouse 
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blastocysts by standard procedures.  The GRAF2gt strain was established using # independent 
chimeras that demonstrated germline transmission when bred to wild-type C57bl6 mice. 
Homozygous GRAF2gt/gt mice were generated by crossing F1 GRAF2gt/+ mice.  GRAF2fl/fl 
mice were generated by crossing GRAF2gt/gt mice to flippase (Flp) mice.  Tamoxifen inducible 
SM-specific knockout mice were created by crossing GRAF2fl/fl females to SM MHC-CreERT2 
males.  All experiments were performed using age, sex and littermate genetic controls.  
Animal husbandry was provided by staff within the University of North Carolina Division of 
Comparative Medicine and all animal procedures were approved by our accredited American 
Association for Accreditation of Laboratory Animal Care committee and the Institutional 
Animal Care and Use Committee.  
 
LacZ tissue staining 
Tissues from GRAF2 mice were processed for LacZ staining using previously published 
methods257.  Briefly, tissues were rinsed in 1 × phosphate-buffered saline (PBS) and fixed in 
4% paraformaldehyde (PFA) for 20 min at room temperature.  After three 10-min washes in 
wash buffer (0.1 M phosphate buffer (pH 7.3), 0.1% sodium deoxycholate, 0.02% NP-40, 
0.05% bovine serum albumin (Sigma)), tissues were incubated 30 min to overnight at RT in 
X-Gal staining solution (wash buffer containing 1 mg of X-Gal ml−1 (Sigma), 5 mM 
ferrocyanide and 5 mM ferricyanide).  Tissues were then post fixed in the appropriate fixative, 





Cells or tissues were lysed in RIPA buffer + 0.5% Triton with protease and phosphatase 
inhibitors.  Protein concentration was determined by using a colorimetric BCA assay (Pierce). 
Lysates were electrophoresed on 10-15% SDS-PAGE gels, transferred to PVDF membrane and 
immunoblotted with specific antibodies as indicated using a 1:1000 dilution.  GRAF2 antibody 
was from Proteintech; myosin heavy chain (MHC), smooth muscle alpha actin (SMA), and 
calponin (CNN) antibodies were from Abcam; GAPDH antibody was from Novus Biologicals; 
alpha-tubulin antibody was from Sigma.  Blots were washed in TBST (TBS plus 0.05% Triton 
X), followed by incubation with horseradish peroxidase conjugated secondary antibodies 
(Amersham) at a 1:2,000 dilution.  Blots were visualized after incubation with chemiluminscence 
reagents (ECL, Amersham). 
 
Blood Pressure Measurements 
Conscious blood pressure was measured in male mice aged 12–16 weeks using a tail cuff 
detection system (CODA High Throughput System, Kent Scientific).  Briefly, mice were 
restrained in CODA animal holders and placed on a warming platform, heated to 38°C.  Once 
tails reached 32°C, cuffs were placed on tails.  Mice were subjected to 30 measurements over 
a period of 30 min taken every day (between 08:00 and 10:00) for 10 consecutive days as 
previously described258.  Data are presented as an average of measurements on the final 3 
days.  
 
Cell culture and Immunofluorescent Staining 
HuAoSMC were purchased from Lonza and maintained in smooth muscle growth medium-2 
(SmGM-2) supplemented with growth factors and 5% FBS.  Rat aortic smooth muscle cells 
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(RaAoSMC) were maintained in DMEM-F12 media (Gibco), supplemented with 10% fetal 
bovine serum and 0.5% penicillin/streptomycin. Cells were transfected with HA-GRAF2 
plasmids using Trans-IT (Mirus Bio) transfection reagents according to manufacturer’s protocol.  
After 24 hours, cells were permeabilized, blocked and incubated with primary mouse anti-HA 
antibody overnight (Cell Signaling).  After washing with PBS, slides were incubated for 1 
hour with Alexa Fluor488-Goat anti mouse antibody or 555-conjugated phalloidin 
(Invitrogen).  Cells were imaged at 40X on a Zeiss 700 Confocal Laser Scanning Microscope.  
 
siRNA knockdowns  
The following siRNAs were obtained from Invitrogen: nontargeted control (NTC) siRNA (to 
GFP) 5′-GGUGCGCUCCUGGACGUAGCC-3′, GRAF2 5′- [dT][dT]-3′ (sense) and 5′- 
[dT][dT]-3′ (antisense). GRAF3 5′- [dT][dT]-3′ (sense) and 5′- [dT][dT]-3′ (antisense).  GRAF2 
and GRAF3 siRNA was obtained as a sense/antisense mixture. HuAoSMCs were transfected 
with 50 nM GRAF2 or NTC siRNA using Dharmafect siRNA transfection reagent (Dharmacon). 
HuAoSMCs were harvested 72 hours after knockdown. 
 
Quantitative PCR 
RNA was isolated from cells or tissues using RNeasy Mini Kit (Qiagen).  RNA was treated with 
DNase (Qiagen) to eliminate contaminating genomic DNA.  RNA underwent first-strand cDNA 
synthesis using the iScript cDNA synthesis kit (Bio-Rad).  Twenty nanograms cDNA was used 
in quantitative or semiquantitative PCR assays.  Semiquantitative PCR primers used were: Real-






For L-NAME experiment, mice were treated with L-NAME in drinking water (450 mg/L) for 14 
days.  Renin Transgenic mice (RTG), developed by Oliver Smithies’ Lab, endogenously express 
less renin and exhibit higher BP.  All groups were maintained on standard chow. 
 
Pulse Wave Velocity 
Pulse Wave Velocity  (PWV) was calculated for 10 month old WT and GRAF2gt/gt mice (n=6 per 
group).  In brief, blood flow was recorded using a 20-MHz pulsed Doppler probe at the levels of 
the carotid and femoral arteries, and PWV was calculated by dividing the separation distance by 
the difference in pulse wave arrival time in respect to ECG R-peaks as previously reported259. 
 
Statistics 
All data represent at least 3 individual experiments and are presented as means ± standard 
deviation.  Means were compared by Student’s t-test and statistical significance is reported 
as p-values.  Sample sizes were chosen based on an extensive literature search and standard 
exclusion criterion of two standard deviations from the mean were applied.  Band intensities 










Figure 3.1  Smooth muscle specificity of GRAF2 and GRAF3 gene expression in humans 
(previous page).  Gene expression of (A) GRAF2 (ARHGAP10) and (B) GRAF3 (ARHGAP42) 
in human tissues from GTEx database.  Images provided by GTEx consortium 









Figure 3.2  Generation of GRAF2 depleted mice. Schematic detailing the “knockout first” 
strategy for creating genetrap (GRAF2gt/gt) or conditional knockout (GRAF2fl/fl) mice. IRES, 






Figure 3.3  Novel GRAF2 deficient mouse model. (A) GRAF2 expression pattern revealed by 
whole mount Lac Z staining (blue) or by dual immunohistochemical staining (in frozen 
section) for β-GAL (green), SM a-actin (red), (DAPI, blue) from GRAF2gt/+ mice.  No 
significant LacZ staining or β-GAL immunofluorescence was observed in tissues from Wt 
mice. Mes., mesenteric.  Western analysis of GRAF2 depletion in bladders from (B) GRAF2gt/gt 
mice and (C) GRAF2fl/fl SM MHC-CreERT2 mice (treated with tamoxifen, 100mg/kg via oral 







Figure 3.4  GRAF2 deficiency leads to increased basal blood pressure. (A) systolic pressure, 
(B) diastolic pressure, (C) mean arterial pressure, and (D) heart rate of 12-16 week old male 
GRAF2gt/gt or WT mice measured via tail cuff.  Data are expressed as mean ± SD; n=3 for WT 





Figure 3.5  GRAF2 regulates SMC phenotypes. (A) Expression of HA-GRAF2 (arrow, red) in 
RaAoSMC markedly attenuated stress fiber formation, while (B) depletion by siRNA 
significantly induced contractile protein levels in HuAoSMC and RaAoSMC. (C) and (D) 
RaAoSMC depletion of GRAF2 (and GRAF3) by siRNA significantly increased collagen 
production. (E) Aortas from hypertensive mice treated with L-NAME for 14 days or renin 
transgenic (RTG) mice show an increase in GRAF2 expression. (F) Collagens are significantly 
increased in aortas from tamoxifen treated GRAF2fl/fl SMMHCCreERT2 mice (G) Pulse Wave 
Velocity of WT or GRAF2gt/gt mice (n=3, n=5, respectively). *p<0.05 vs. control (Ctrl) or WT 




CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
 
4.1 Summary of work and future directions 
The studies presented in this dissertation reveal the importance of GRAF2 and GRAF3 in 
blood pressure homeostasis, SMC contractility, and vessel compliance.  The data herein 
reinforce the importance of RhoA signaling in CVD development and strengthen our 
understanding of the vascular contribution to HTN.  The initial purpose of these studies was to 
assess the therapeutic potential of GRAF3.  In Chapter 2, we show for the first time that 
overexpression of GRAF3 in SMC has the capability to significantly decrease systolic blood 
pressure in normotensive and hypertensive mice.  Furthermore, we discovered that stretch-
activation of Src and FAK kinases lead to phosphorylation of GRAF3 at Y376, relieving 
GRAF3’s autoinhibition.  Activation of GRAF3 reduces RhoA activity and decreases 
phosphorylation of MLC in SMC.  Recent analysis has shown that GRAF2 is more highly 
expressed than GRAF3 in human smooth-muscle tissues, so studies in Chapter 3 sought to 
understand the role of GRAF2 in blood pressure homeostasis.  We found that GRAF2 depletion 
in mice results in significantly increased systolic, diastolic, and mean arterial pressure.  
Moreover, depletion of GRAF2 leads to an increase in SM contractile gene expression and an 
increase in collagens.  Coupled with the fact that GRAF2 depleted mice have significantly 
increased pulse wave velocity, this indicates that GRAF2 may play a role in arterial stiffening as 
well as blood pressure regulation.   
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While our collective work has made significant contributions to the field, it has also 
prompted many unanswered questions.  Excitingly, we found that once mice overexpressed 
GRAF3RQ, their blood pressure significantly decreased and were able to consistently stay lower 
than their non-overexpressing counterparts, even after being subjected to L-NAME induced 
HTN.  Moving forward, it will be necessary to test whether overexpressing GRAF3RQ after the 
induction of HTN would effectively lower BP.  This would more accurately mimic hypertensive 
treatment in humans, where patients seek treatment for HTN after they are diagnosed rather than 
seek preventative care prior to symptoms.  It would also be interesting to test the widespread 
ability of GRAF3 overexpression to prevent or reverse BP increases in other models of essential 
HTN, each of which works through a different mechanism and imitates different features found 
in human HTN233, 260.  L-NAME treatment prevents dilation by inhibiting nitric oxide synthase.  
DOCA on the other hand is an aldosterone precursor that imitates the effects of 
mineralocorticoid and glucocorticoids, recapitulating both volume overload and increased 
sympathetic neural signaling and AII infusion is part of the renin-angiotensin-aldosterone system 
that modulates renal sodium handling.   
 More and more emphasis has been placed on the need to study sex differences in CVD.  
Although men have higher incidence rates of CVD than age-matched premenopausal women, 
that pattern is reversed post-menopause261.  Sex differences relating to CVD have been observed 
in animals, as well.  For example, spontaneously hypertensive rats show age-dependent increases 
in BP that are greater in males than females261.  In pharmacologically induced models of HTN, 
these differences can be as great as 30 or 50 mmHg between males and females261.  While many 
studies attribute these differences to hormones, that is not exclusively the case.  Therefore, it 
would be of interest to explore if GRAF3 overexpression has different effects on BP in males 
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and females.  One limitation of our current GRAF3 SM-specific overexpression mouse model is 
that we are only able to study males; the SMMHCCreERT2 line is currently the most specific and 
robust SMC-specific Cre line available, however, this BAC transgene was randomly 
incorporated into to the Y chromosome.  To this end, there is a SM22-CreERT2 line available that 
will enable SMC-selective recombination in adults in both sexes.  It should be noted, however, 
that there is some concern that this Cre is expressed in myeloid cells in addition to SMC262, so 
more work would have to be done to show that the overexpression in SMC is the cause of any 
seen effects.     
Another well-documented and relevant factor in HTN and CVD development is age, but 
it’s estimated that aging is only studied in 4% of all NIH-funded HTN studies233, 263.  The onset 
of CVD doesn’t usually occur in humans until middle- or old- age.  Hypertension studies, 
including our own, are not always performed at the equivalent later ages in mice.  Whereas 
human middle- and old- age are considered from 38-47 years and 55-69 years respectively, in 
mice these age groups are considered from 10-14 months and 18-24 months (Table 4.1) 264.  It 
would be of clinical importance therefore, to study the effect of short and long term GRAF3 
overexpression in aged mice.   
In Chapter 2 we presented a molecular model of GRAF3 that is supported by our 
experimental findings that the GRAF3 BAR-PH domains autoinhibit GRAF3’s GAP domain and 
that Y376 is in a location accessible for phosphorylation and activation.  We built this model 
from similarly structured Appl1 and GRAF1 because the structure of GRAF3 is currently 
unsolved.  This is because GRAF3 is hard to solubilize and therefore hard to crystalize.  But, as 
crystallization methods advance, we hope to be able to solve the structure of GRAF3 (or at least 
parts of it) and current collaborations are actively trying this.  Having the correct 3D structure of 
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GRAF3 would give us a better view of “accessibility” and binding pockets for kinases and 
proteins to interact with GRAF3.  It could also be used to make predictions of lead compounds 
for small molecule activators of GRAF3.  The data in this dissertation support the idea that 
GRAF3 would make a good HTN therapeutic target.  In lieu of or alongside crystalizing GRAF3, 
we can take advantage of small molecule drug screens that are being made more widely available 
to look for compounds that increase the GAP activity of GRAF3.  This strategy is also actively 
underway.  Taking advantage of GRAF3’s autoinhibitory mechanism, we can individually 
validate the compounds by a bioluminescence resonance energy transfer (BRET) assay, where 
Renilla luciferase is placed on the N-terminus of the BAR domain and fluorescent protein is 
placed on the C-terminus of the GAP domain.  When GRAF3 is in the closed, inactive 
conformation, the luciferase and the GFP would be in close enough proximity that the luciferase 
would stimulate the GFP and give off BRET signal.  When GRAF3 is in the open, active 
conformation, the luciferase and GFP would be too far away from one another and no BRET 
signal would occur.  Living cells containing the BRET-GRAF3 construct could be treated with 
suspected activating compounds and monitored for a decrease in BRET signal.   
 While the work in this dissertation has focused mainly on the GAP domain activity of 
GRAF3, it would be of interest to characterize the specific functions of each of the domains 
within GRAF3 in the context of SMC to expand our portfolio of GRAF3 drug-targeting 
strategies.  BAR domains are known for their ability to sense and form membrane curvature 218 
while  PH domains bind to phosphatidyl lipids found in biological membranes and help recruit 
proteins to specific membranes, mediating appropriate cellular compartmentalization or signal 
transduction interactions265.  In fibroblasts, the GRAF3 PH domain controlled the localization of 
GRAF3 at focal adhesions along the cell periphery208, but this has not been validated in SMC.  
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SH3 domains modulate protein-protein interactions by binding with moderate affinity and 
selectivity to proline-rich ligands266.  SH3 domains have even been known to autoinhibit the 
membrane-binding capabilities of N-Bar and F-Bar domains in the endocytic protein endophillin 
and the dynamin-binding protein syndapin218, 267, 268.  In a study looking at the SH3 domain of 
Rho family GAPs, they additionally found that the GRAF1 SH3 interacts with PKN3 and PTK2, 
which play roles in focal adhesion turnover and actin depolymerization208, 217.  They found that 
the GRAF2 SH3 domain binds to ASAP2 (recruits paxillin to focal adhesions), TLN1 
(component of focal adhesion), and DNAH6 (cytoskeletal motor protein), suggesting that 
GRAF1 and GRAF2 may play different roles in focal adhesion assembly217.  They also found 
that GRAF3 SH3 domain binds to MYH14 (myosin heavy chain), DBN1 ( F-actin binding), 
LRRFIP2 (formin regulatory protein), or FHOD3 (formin actin nucleation and elongation)217. 
Furthermore, the SH3 domain of GRAF1 and GRAF3 have been shown to be necessary for its 
localization to focal adhesions and actin stress fibers208.  None of these interactions, however, 
have been validated in SMC.   
Another focus in this dissertation has been to show the importance of the phosphorylation 
of GRAF3 at Y376, but there are other sites on GRAF3 that are predicted to be post-
translationally modified as well (Figure 4.1C).  For example, S152 is part of a consensus 
binding site for MAPK, which is known to be activated by G-protein signaling from 
vasoconstrictive agonists acting on GPCRs on the SMC surface.  This serine is part of a 
serine/lysine/aspartic acid triad that our model predicts would undergo a conformational shift 
when the serine is phosphorylated (Figure 4.2A).  This phosphorylation could drive the BAR 
and PH domains away from one another, causing the GAP domain to “pop up”.  Our preliminary 
work shows that SMCs transfected with a phospho-deficient version of GRAF3 (S152A) show 
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normal stress fiber clearing.  Smooth muscle cells transfected with a phospho-mimetic version of 
GRAF3 (S152D), however, show enhanced stress fiber formation, indicating that GRAF3 
phosphorylation at S152 favors the closed, inactive version of GRAF3 (Figure 4.2B and 4.3).  
Stress fiber formation is further exacerbated when SMC transfected with GRAF3 S152D are also 
treated with the vasoconstrictor S1P (Figure 4.2B).  A radioactive kinase assay revealed that p38 
delta is a MAPK capable of phosphorylating GRAF3 at S152 (Figure 4.2C) and SMCs show 
decreased phosphorylation of  GRAF3 at S152 and decreased pERK signaling when Rho is 
inhibited pharmacologically (Figure 4.2D).  This supports the idea of another branch of the 
RhoA/contraction/GRAF3 feedback loop, in which vasoconstrictive agonists have a more direct 
effect on GRAF3 than previously thought before (Figure 4.3).  It would be interesting to not 
only explore this S152 phosphorylation-activity relationship in more depth using similar studies 
as those performed in this dissertation, but it would also be interesting to test whether GRAF3 
S152 dephosphorylation and concurrent GRAF3 Y376 phosphorylation would result in stronger, 
more dramatic RhoA inhibition.  While Y376 and Y792 are the top hits on PhosphoSite Plus, 
S152 was not listed at all, despite displaying importance experimentally.  This opens the door for 
the possibility of other important, still unidentified sites of phosphorylation as well.   
GRAF2 and GRAF3 share nearly 48% of their amino acid sequence (according to 
UniProt alignment).  This percentage jumps to 65, 56, 62, and 59% when the BAR, PH, GAP, 
and SH3 domains, respectively, are individually compared. Despite this similarity, 
PhosphoSitePlus analysis has not identified the same residues on both proteins as the major sites 
of phosphorylation (Figure 4.1).  While there seem to be similar regions on GRAF2 and GRAF3 
that are both post-translationally modified, Y376 and Y792 stand out in GRAF3 and S591 stands 
out in GRAF2 as the most-likely sites for phosphorylation.  While Y376 and (to some extent, 
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albeit minimal) Y792 have been explored in this dissertation, no work has been done to validate 
or explore the significance of S591 in GRAF2 and this would be a good place to start teasing out 
the mechanism of GRAF2.  Our molecular modeling analysis of GRAF3 revealed a site of 
interest that was not identified by PhosphoSitePlus, so it is possible that there are other residues 
of importance on GRAF2 besides S591 that could be of interest.  
Shown in Chapter 3 and in experiments not shown in this dissertation, we have evidence 
that GRAF2 and GRAF3 exhibit some degree of compensation.  GRAF2 depletion results in 
compensatory up-regulation of GRAF3 while co-depletion of both GRAFs 
(GRAF2gt/gt/GRAF3gt/gt) led to embryonic lethality.  Thus, it has not yet been possible to assess 
the combinatorial roles of GRAF2 and GRAF3 in the control of BP in adult animals.  We are 
currently in the process of generating GRAF2/3fl/flSMMHCCreERT2 mice which will allow us to 
knockout both GRAFs in a SMC-specific- and tamoxifen-dependent manner and assess BP and 
vessel tone effects.  
HTN and vascular stiffness are currently caught in a “chicken or the egg” debate.  For a 
long time it has been thought that HTN precedes aortic stiffening, but this paradigm has been 
called into question recently269.  Five different animal models of HTN or vascular disorder 
showed that increased aortic stiffness preceded increased BP and this timing reversal is also 
supported in humans by the Framingham study270-275.  Thus far we have found that GRAF2 
depleted mice have increased collagen expression and increased PWV, indicating that GRAF2 
may be involved in regulation of vessel compliance, but more thorough analysis is needed.  To 
parse out the role of GRAF2 in the timing of stiffness vs HTN, we can measure BP and PWV at 
different time points in our GRAF2gt/gt mice.  Because these mice are deficient from birth, there is 
a chance we could see no significant progression of stiffness overtime.  In this case, we can 
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monitor BP and PWV in GRAF2fl/fl SMMHC-CreERT2 mice before and multiple timepoints after 
tamoxifen treatment.  Furthermore, we can stain artery sections from these different timepoints 
with collagen and elastin markers and check for expression of matrix metalloproteinases, which 
contribute to vascular stiffness through extracellular matrix remodeling.  
 Shortly after our initial discovery that GRAF2 is more highly expressed than GRAF3 in 
SM tissues in humans, we noticed the expression of splice variants in these SM tissues (Figure 
4.4).  Whereas GRAF3 has 1 clear dominant isoform, GRAF2 has 3 prevailing isoforms—1 
dominant and 2 less dominant, that are missing exons1-9, 21, and 23.  These 2 less dominant 
isoforms are missing the BAR domain of GRAF2, but have fully intact PH and GAP domains.  It 
would be interesting to test how active/functional the less dominant isoforms are and to test if 
similar GRAF2 isoforms exist in mice.  
 
4.2  Concluding remarks 
Hypertension is known as the silent killer because it has no obvious symptoms most of 
the time.  It’s the most common chronic disease in Americans, yet HTN still proves to be 
challenging to treat.  Overall, the studies in this dissertation conclude that GRAF2 and GRAF3 
are important regulators of blood pressure homeostasis, SMC contractility, vessel tone, and 
vessel compliance.  These studies support the GRAFs as an essential component in a pressure-
sensing feedback loop within smooth muscles. With the aid of further investigations, this work 
could lead to the development of novel antihypertensive treatments that dually function as anti-




4.4  Figures 
 
 Age Range 
Mature Adult Middle Age Old Age 
Mouse 3-6 months 10-14 months 18-24 months 
Human 20-30 years 38-47 years 55-69 years 
 
Table 4.1  Comparison between Mouse and Human Ages. Data adapted from Flurkey, Currer, 
and Harrison, 2007. “The mouse in biomedical research” in James G. Fox (ed.), American 







Figure 4.1  Post translational modifications of the GRAF family.  Possible sites of 
phosphorylation (blue), acetylation (green), ubiquitination (tan), or other (gray) post translational 
modifications on (A) GRAF1, (B) GRAF2, and (C) GRAF3, identified by mass-spectrometry 
experiments on the PhosphoSitePlus® database.  Image modified from PhosphoSitePlus® 






Figure 4.2  Phosphorylation of GRAF3 at S152 by p38 delta affects RhoA signaling. (A) 
Spherical (right) and ribbon (left) 3D models showing the same ½ of GRAF3. Color scheme 
follows: BAR 1 (dark purple), BAR 2 (dark green), PH 2 (light green), GAP 2 (yellow), RhoA 
docking sites (pink), C-terminus of PH domain (red), N-terminus of GAP domain (orange).  
Arrow indicates S152, which is part of a conserved serine(S)/aspartic acid (D)/lysine (K) triad.  
(B) When RaAoSMC are transfected with a phospho-deficient mutant (S152A), cells exhibit 
normal stress fiber clearing. Cells transfected with a phospho-mimetic mutant (S152D) exhibit 
enhanced stress fiber formation.  Stress fiber formation is further enhanced when these cells are 
treated with S1P. (C) Radioactive Kinase Assay of WT or S152A isolated GRAF3 BAR-PH 
incubated with active p38 delta.  Radiograph, top and Coomassie stain, bottom. (D). RaAoSMC  
were treated with or without CT04, a Rho inhibitor.  Western analysis shows decreases in 





Figure 4.3  Working model of GRAF3 phosphorylation at S152. Vasoconstrictive signals act 
on GPCRs along the cell membrane of SMCs to promote G-protein signaling which activates 
members of the MAPK family, such as p38 delta.  (A) P38 delta phosphorylates GRAF3 at S152.  
This phosphorylation causes a conformational shift and deactivation of GRAF3, which enhances 
RhoA signaling and results in increased SMC contraction. (B) It is thought that active RhoA 





Figure 4.4   GRAF2 and GRAF3 splice variant expression among human tissues.  Splice 
variant expression among different human tissues for (A) GRAF2 and (B) GRAF3.  Images 




APPENDIX A: ANALYSIS OF GRAF3 GENOTYPE AND BP IN HUMAN POPULATIONS 
 
A group of 346 borderline hypertensive patients (see Appendix B for more detailed 
characteristics of this group) were genotyped as the rs604723 variation using a TaqMan-based 
allelic discrimination assay.  The resulting genotypes were then correlated with repeated office 
BP measurements or HTN status (i.e. greater or less than 140 mmHg) or grouped by race. 
Ap<0.05 vs. diastolic BP measured in patients homozygous for the major allele (C/C); Bp<0.001 
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